DE69535036D1 - Immunomodulatorische oligonukleotide - Google Patents

Immunomodulatorische oligonukleotide

Info

Publication number: DE69535036D1
Authority: DE; Germany
Prior art keywords: oligonucleotides; immunomodulative; stabilised; contain; cpg dinucleotide
Prior art date: 1994-07-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69535036T

Other languages

English (en)

Other versions

DE69535036T2 (de

DE69535036T3 (de

Inventor

M Krieg

Dennis Klinman

Alfred D Steinberg

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY

University of Iowa Research Foundation UIRF

Coley Pharmaceutical Group Inc

US Department of Health and Human Services

Original Assignee

UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY

University of Iowa Research Foundation UIRF

Coley Pharmaceutical Group Inc

US Department of Health and Human Services

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-15

Filing date

1995-02-07

Publication date

2006-07-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23056334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69535036(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-02-07 Application filed by UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, University of Iowa Research Foundation UIRF, Coley Pharmaceutical Group Inc, US Department of Health and Human Services filed Critical UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY

2006-07-20 Application granted granted Critical

2006-07-20 Publication of DE69535036D1 publication Critical patent/DE69535036D1/de

2007-01-18 Publication of DE69535036T2 publication Critical patent/DE69535036T2/de

2011-07-07 Publication of DE69535036T3 publication Critical patent/DE69535036T3/de

2015-02-08 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
230000002519 immonomodulatory effect Effects 0.000 title 1
108091029430 CpG site Proteins 0.000 abstract 1
230000003308 immunostimulating effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Virology (AREA)
General Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Analytical Chemistry (AREA)
Mycology (AREA)
Plant Pathology (AREA)
Hospice & Palliative Care (AREA)

DE69535036T 1994-07-15 1995-02-07 Immunomodulatorische oligonukleotide Expired - Lifetime DE69535036T3 (de)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US27635894A	1994-07-15	1994-07-15
US276358		1994-07-15
EP95911630A EP0772619B2 (de)	1994-07-15	1995-02-07	Immunomodulatorische oligonukleotide
PCT/US1995/001570 WO1996002555A1 (en)	1994-07-15	1995-02-07	Immunomodulatory oligonucleotides

Publications (3)

Publication Number	Publication Date
DE69535036D1 true DE69535036D1 (de)	2006-07-20
DE69535036T2 DE69535036T2 (de)	2007-01-18
DE69535036T3 DE69535036T3 (de)	2011-07-07

Family

ID=23056334

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE69535905T Expired - Lifetime DE69535905D1 (de)	1994-07-15	1995-02-07	Immunomodulatorische Oligonukleotide
DE69535036T Expired - Lifetime DE69535036T3 (de)	1994-07-15	1995-02-07	Immunomodulatorische oligonukleotide

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE69535905T Expired - Lifetime DE69535905D1 (de)	1994-07-15	1995-02-07	Immunomodulatorische Oligonukleotide

Country Status (12)

Country	Link
US (1)	US6194388B1 (de)
EP (4)	EP1167378B1 (de)
JP (7)	JP3468773B2 (de)
AT (3)	ATE328890T1 (de)
AU (1)	AU713040B2 (de)
CA (2)	CA2560114A1 (de)
DE (2)	DE69535905D1 (de)
DK (1)	DK0772619T4 (de)
ES (3)	ES2267100T5 (de)
HK (3)	HK1043598A1 (de)
PT (1)	PT772619E (de)
WO (1)	WO1996002555A1 (de)

Families Citing this family (866)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849719A (en)	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US6727230B1 (en)	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
EP1167378B1 (de) *	1994-07-15	2011-05-11	University of Iowa Research Foundation	Immunomodulatorische Oligonukleotide
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7422902B1 (en) *	1995-06-07	2008-09-09	The University Of British Columbia	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) *	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
AU1463097A (en)	1996-01-04	1997-08-01	Rican Limited	Helicobacter pylori bacterioferritin
EP0879284B1 (de) *	1996-01-30	2009-07-29	The Regents of The University of California	Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
FR2750704B1 (fr)	1996-07-04	1998-09-25	Rhone Poulenc Rorer Sa	Procede de production d'adn therapeutique
US5856462A (en) *	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
AU768178B2 (en) *	1996-10-11	2003-12-04	Regents Of The University Of California, The	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
US6610661B1 (en)	1996-10-11	2003-08-26	The Regents Of The University Of California	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (de) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
CA2281838A1 (en) *	1997-02-28	1998-09-03	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
EP2172216A3 (de) *	1997-03-10	2010-11-24	Ottawa Hospital Research Institute	Verwendung von Nukleinsäuren, die unmethylierte CPG-Dinukleotide enthalten als Adjuvantien
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en)	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US20030104044A1 (en) *	1997-05-14	2003-06-05	Semple Sean C.	Compositions for stimulating cytokine secretion and inducing an immune response
WO1998051278A2 (en)	1997-05-14	1998-11-19	Inex Pharmaceuticals Corporation	High efficiency encapsulation of charged therapeutic agents in lipid vesicles
AU7589398A (en) *	1997-05-19	1998-12-11	Merck & Co., Inc.	Oligonucleotide adjuvant
CA2301575C (en)	1997-05-20	2003-12-23	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) *	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP1374894A3 (de) *	1997-06-06	2004-09-22	Dynavax Technologies Corporation	Immunstimulierende Oligonukleotide, Zusammensetzungen und Verwendungen davon
WO1998055495A2 (en)	1997-06-06	1998-12-10	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
WO1999011275A2 (en)	1997-09-05	1999-03-11	The Regents Of The University Of California	Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
GB9724531D0 (en)	1997-11-19	1998-01-21	Smithkline Biolog	Novel compounds
PT1053325E (pt)	1998-02-05	2006-05-31	Glaxosmithkline Biolog Sa	Derivados de antigenios associados a tumores da familia mage e, sequencias de acidos nucleicos que os codificam, utilizados para a preparacao de proteinas de fusao e de composicoes para vacinacao.
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
CA2323929C (en) *	1998-04-03	2004-03-09	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO1999052549A1 (en) *	1998-04-09	1999-10-21	Smithkline Beecham Biologicals S.A.	Adjuvant compositions
GB9808866D0 (en)	1998-04-24	1998-06-24	Smithkline Beecham Biolog	Novel compounds
AU3884199A (en) *	1998-05-06	1999-11-23	Ottawa Health Research Institute	Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
CA2328406A1 (en) *	1998-05-14	1999-11-18	Hermann Wagner	Methods for regulating hematopoiesis using cpg-oligonucleotides
RU2244547C2 (ru)	1998-05-19	2005-01-20	Рисерч Дивелопмент Фаундейшн	Тритерпеновые композиции и способы их применения
JP2002516294A (ja) *	1998-05-22	2002-06-04	ローブヘルスリサーチインスティチュートアットザオタワホスピタル	粘膜免疫を誘導するための方法および産物
KR19990086271A (ko) *	1998-05-27	1999-12-15	손경식	면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
US6881561B1 (en)	1998-05-27	2005-04-19	Cheil Jedang Corporation	Endonuclease of immune cell, process for producing the same and immune adjuvant using the same
US6562798B1 (en) *	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) *	1998-06-25	2004-02-17	National Jewish Medical And Research Center	Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) *	1998-06-25	2004-12-09	Dow Steven W.	Systemic immune activation method using nucleic acid-lipid complexes
AU764532B2 (en) *	1998-07-27	2003-08-21	University Of Iowa Research Foundation, The	Stereoisomers of CpG oligonucleotides and related methods
ES2318898T3 (es)	1998-07-31	2009-05-01	International Institute Of Cancer Immunology, Inc.	Antigenos tumorales basados en el producto del gen wt1 supresor de tumor.
TR200100373T2 (tr)	1998-08-07	2001-09-21	University Of Washington	İmünolojik uçuk virüsü antijenleri ve bunların kullanım yöntemleri
DK1104306T3 (da) *	1998-08-10	2006-05-22	Antigenics Inc	Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
ES2394458T3 (es) *	1998-09-09	2013-01-31	Genzyme Corporation	Metilación de vectores plasmídicos
FR2783170B1 (fr) *	1998-09-11	2004-07-16	Pasteur Merieux Serums Vacc	Emulsion immunostimulante
US6692752B1 (en)	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
JP2003524602A (ja) *	1998-09-18	2003-08-19	ダイナバックステクノロジーズコーポレイション	ＩｇＥ関連疾患の治療方法と、その治療において使用する組成物
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
WO2000020039A1 (en) *	1998-10-05	2000-04-13	The Regents Of The University Of California	Methods and adjuvants for stimulating mucosal immunity
CZ301212B6 (cs)	1998-10-16	2009-12-09	Smithkline Beecham Biologicals S. A.	Vakcinacní prostredek
WO2000034482A2 (en)	1998-12-08	2000-06-15	Smithkline Beecham Biologicals S.A.	Novel compounds derived from neisseria meningitidis
ES2346832T3 (es)	1998-12-08	2010-10-20	Corixa Corporation	Compuestos y metodos para el tratamiento y el diagnostico de una infeccion clamidial.
US20020119158A1 (en)	1998-12-17	2002-08-29	Corixa Corporation	Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en)	1998-12-28	2003-06-17	Corixa Corporation	Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7198920B1 (en)	1999-01-29	2007-04-03	Corika Corporation	HER-2/neu fusion proteins
WO2000045849A2 (en) *	1999-02-05	2000-08-10	Genzyme Corporation	Use of cationic lipids to generate anti-tumor immunity
ATE464907T1 (de) *	1999-02-17	2010-05-15	Csl Ltd	Immunogene komplexe und methoden in bezug auf diese
US8206749B1 (en)	1999-02-26	2012-06-26	Novartis Vaccines And Diagnostics, Inc.	Microemulsions with adsorbed macromolecules and microparticles
CA2371994C (en)	1999-02-26	2010-09-28	Guido Grandi	Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs
ES2337650T3 (es)	1999-03-12	2010-04-28	Glaxosmithkline Biologicals S.A.	Polipeptidos antigenicos de neisseria meningitidis polinucleotidos y anticuerpos protectores correspondientes.
JP2000262247A (ja) *	1999-03-19	2000-09-26	Asama Kasei Kk	免疫調節剤、免疫調節食品および免疫調節飼料
FR2790955B1 (fr) *	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
TR200102739T2 (tr)	1999-03-19	2001-12-21	Smithkline Beecham Biologicals S.A.	Aşı
GB9909077D0 (en)	1999-04-20	1999-06-16	Smithkline Beecham Biolog	Novel compositions
EP1169347B1 (de)	1999-04-02	2008-07-02	Corixa Corporation	Verbindungen und verfahren für therapie und diagnose von lungenkrebs
US6977245B2 (en) *	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
WO2000061151A2 (en)	1999-04-12	2000-10-19	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US6558670B1 (en)	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
CZ303515B6 (cs)	1999-04-19	2012-11-07	Smithkline Beecham Biologicals S. A.	Adjuvantní prostredek
AU4978100A (en) *	1999-04-29	2000-11-17	Coley Pharmaceutical Gmbh	Screening for immunostimulatory dna functional modifyers
GB9915204D0 (en) *	1999-06-29	1999-09-01	Smithkline Beecham Biolog	Vaccine
ES2250151T3 (es) *	1999-06-29	2006-04-16	Glaxosmithkline Biologicals S.A.	Uso de cpg como adyuvante de vacuna contra vih.
US6514948B1 (en)	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
FR2795963A1 (fr) *	1999-07-08	2001-01-12	Pasteur Merieux Serums Vacc	Polynucleotide immunostimulant
SK782002A3 (en) *	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
GB9918319D0 (en)	1999-08-03	1999-10-06	Smithkline Beecham Biolog	Vaccine composition
US20050226890A1 (en) *	1999-08-12	2005-10-13	Cohen David I	Tat-based vaccine compositions and methods of making and using same
CA2380947C (en)	1999-08-19	2011-11-01	Dynavax Technologies Corporation	Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
MXPA02002107A (es) *	1999-08-27	2003-08-20	Inex Pharmaceuticals Corp	Composiciones para estimular la secrecion de citoquina e inducir una respuesta inmune.
DK1221955T3 (da) *	1999-09-25	2006-01-30	Univ Iowa Res Found	Immunstimulerende nukleinsyre
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
CA2721011A1 (en)	1999-10-22	2001-05-03	Aventis Pasteur Limited	Modified gp100 and uses thereof
US7223398B1 (en)	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
WO2001045750A1 (en) *	1999-12-21	2001-06-28	The Regents Of The University Of California	Method for preventing an anaphylactic reaction
AU2001227889A1 (en) *	2000-01-14	2001-07-24	The United States of America, represented by The Secretary, Department of Health & Human Services	Oligodeoxynucleotide and its use to induce an immune response
AT409085B (de) *	2000-01-28	2002-05-27	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US6552006B2 (en)	2000-01-31	2003-04-22	The Regents Of The University Of California	Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
FR2805264B1 (fr) *	2000-02-18	2002-04-12	Aventis Pasteur	Oligonucleotides immunostimulants
FR2805265B1 (fr) *	2000-02-18	2002-04-12	Aventis Pasteur	Oligonucleotides immunostimulants
CA2399550A1 (en) *	2000-02-23	2001-08-30	The Regents Of The University Of California	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
WO2001062778A2 (en)	2000-02-23	2001-08-30	Smithkline Beecham Biologicals S.A.	Tumour-specific animal proteins
US20030130217A1 (en) *	2000-02-23	2003-07-10	Eyal Raz	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040131628A1 (en) *	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US20010046967A1 (en)	2000-03-10	2001-11-29	Gary Van Nest	Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020098199A1 (en)	2000-03-10	2002-07-25	Gary Van Nest	Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en)	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
US7129222B2 (en)	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
US7157437B2 (en)	2000-03-10	2007-01-02	Dynavax Technologies Corporation	Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
CA2405424A1 (en) *	2000-04-07	2001-10-18	The Regents Of The University Of California	Synergistic improvements to polynucleotide vaccines
WO2001081379A2 (en)	2000-04-21	2001-11-01	Corixa Corporation	Compounds and methods for treatment and diagnosis of chlamydial infection
AU2001258102B2 (en)	2000-05-10	2007-03-01	Aventis Pasteur Limited	Immunogenic polypeptides encoded by mage minigenes and uses thereof
WO2001090129A2 (en)	2000-05-19	2001-11-29	Corixa Corporation	Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
SI1542732T1 (sl)	2000-06-20	2010-01-29	Corixa Corp Csc The United Sta	Fuzijski proteini Mycobacterium tuberculosis
EP1296714B1 (de)	2000-06-22	2009-08-26	University Of Iowa Research Foundation	Kombination von CpG und Antikörpern gegen CD19,CD20,CD22 oder CD40 zur Prävention oder Behandlung von Krebs.
DE60134158D1 (de)	2000-06-28	2008-07-03	Corixa Corp	Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
GB0108364D0 (en)	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
EA006313B1 (ru)	2000-06-29	2005-10-27	Глаксосмитклайн Байолоджикалс С.А.	Поливалентные иммуногенные композиции и способы их применения
US7229623B1 (en)	2000-08-03	2007-06-12	Corixa Corporation	Her-2/neu fusion proteins
KR100917101B1 (ko) *	2000-08-04	2009-09-15	도요 보세키 가부시키가이샤	플렉시블 금속적층체 및 그 제조방법
WO2006033665A1 (en) *	2004-03-16	2006-03-30	Inist Inc.	Tat-based vaccine compositions and methods of making and using same
UA79735C2 (uk)	2000-08-10	2007-07-25	Глаксосмітклайн Байолоджікалз С.А.	Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
WO2002011761A2 (en) *	2000-08-10	2002-02-14	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Vaccine against rsv
WO2005090392A1 (en) *	2004-03-16	2005-09-29	Inist Inc.	Tat-based tolerogen compositions and methods of making and using same
CA2420499A1 (en) *	2000-08-25	2002-02-28	Yeda Research And Development Co. Ltd.	Methods of treatment or prevention of autoimmune diseases with cpg-containing polynucleotide
GB0022742D0 (en)	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
AU2001291096A1 (en) *	2000-09-15	2002-03-26	Coley Pharmaceutical Gmbh	Process for high throughput screening of CpG-based immuno-agonist/antagonist
DK1889630T3 (da)	2000-10-18	2012-03-05	Glaxosmithkline Biolog Sa	Vacciner omfattende MAGE-antigen koblet til protein D-fragment
DE60139563D1 (de)	2000-10-27	2009-09-24	Craig J Venter Inst Inc	Nukleinsäuren und proteine von gruppen a und b-streptokokken
US6677347B2 (en) *	2000-12-08	2004-01-13	3M Innovative Properties Company	Sulfonamido ether substituted imidazoquinolines
ATE398175T1 (de)	2000-12-08	2008-07-15	Coley Pharmaceuticals Gmbh	Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
JP2008531580A (ja) *	2000-12-08	2008-08-14	スリーエムイノベイティブプロパティズカンパニー	免疫応答修飾因子の標的化送達のための組成物および方法
US20030049266A1 (en) *	2000-12-27	2003-03-13	Fearon Karen L.	Immunomodulatory polynucleotides and methods of using the same
EP1358885A1 (de) *	2001-01-12	2003-11-05	Amato Pharmaceutical Products, Ltd.	Antiallergische mittel
WO2002055090A1 (fr) *	2001-01-12	2002-07-18	Amato Pharmaceutical Products,Ltd.	Agents preventifs d'infections microbiennes
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
JPWO2002060457A1 (ja) *	2001-01-24	2004-05-27	天藤製薬株式会社	抗ストレス剤
DE10105234A1 (de)	2001-02-02	2002-08-29	Schoeller Textil Ag Sevelen	Textile Fläche
GB0103171D0 (en)	2001-02-08	2001-03-28	Smithkline Beecham Biolog	Vaccine composition
GB0105360D0 (en) *	2001-03-03	2001-04-18	Glaxo Group Ltd	Chimaeric immunogens
ES2298353T3 (es)	2001-03-22	2008-05-16	International Institute Of Cancer Immunology, Inc.	Peptido wt1 modificado.
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
WO2002089747A2 (en)	2001-05-09	2002-11-14	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
JP4188092B2 (ja)	2001-05-21	2008-11-26	インターツェル・アクチェンゲゼルシャフト	免疫促進性オリゴデオキシ核酸分子
US6818787B2 (en) *	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
US7785610B2 (en) *	2001-06-21	2010-08-31	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—III
PT1404873E (pt) *	2001-06-21	2013-07-30	Dynavax Tech Corp	Compostos de imunomodulação quiméricos e métodos de utilização dos mesmos
CA2451739A1 (en) *	2001-06-29	2003-01-09	Chiron Corporation	Hcv e1e2 vaccine compositions
US20030108565A1 (en)	2001-07-10	2003-06-12	Johnson Mark E.	Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
US20030148316A1 (en) *	2001-08-01	2003-08-07	Lipford Grayson B.	Methods and compositions relating to plasmacytoid dendritic cells
US20030072762A1 (en) *	2001-08-03	2003-04-17	Van De Winkel Jan G. J.	Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance Fc receptor-mediated immunotherapies
CA2456328C (en) *	2001-08-07	2015-05-26	Dynavax Technologies Corporation	Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
AU2002361468A1 (en)	2001-08-14	2003-03-18	The Government Of The United States Of America As Represented By The Secretary Of Health And Human S	Method for rapid generation of mature dendritic cells
US7361352B2 (en)	2001-08-15	2008-04-22	Acambis, Inc.	Influenza immunogen and vaccine
SG177000A1 (en)	2001-08-17	2012-01-30	Coley Pharm Gmbh	Combination motif immune stimulatory oligonucleotides with improved activity
DK1567641T3 (da)	2001-08-24	2012-08-27	Uvic Industry Partnerships Inc	Proaerolysin indeholdende proteaseaktiveringssekvenser og fremgangsmåder til anvendelse til behandling af prostatacancer.
WO2003020889A2 (en) *	2001-08-30	2003-03-13	3M Innovative Properties Company	Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
IL160561A0 (en) *	2001-09-07	2004-07-25	Univ Boston	Method and composition for treating immune complex associated disorders
WO2003024480A2 (en) *	2001-09-14	2003-03-27	Cytos Biotechnology Ag	In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US20030099668A1 (en)	2001-09-14	2003-05-29	Cytos Biotechnology Ag	Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
CA2461056A1 (en)	2001-09-20	2003-03-27	Glaxo Group Limited	Hiv-gag codon-optimised dna vaccines
US7514415B2 (en)	2002-08-01	2009-04-07	The United States Of America As Represented By The Department Of Health And Human Services	Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
WO2003027313A2 (en)	2001-09-24	2003-04-03	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20030119774A1 (en) *	2001-09-25	2003-06-26	Marianna Foldvari	Compositions and methods for stimulating an immune response
US20050002951A1 (en) *	2001-09-28	2005-01-06	Haruo Sugiyama	Novel method of inducing antigen-specific t cells
WO2003028757A1 (fr) *	2001-09-28	2003-04-10	Haruo Sugiyama	Nouvelle methode pour induire des lymphocytes t specifiques d'antigenes
AR045702A1 (es)	2001-10-03	2005-11-09	Chiron Corp	Composiciones de adyuvantes.
CA2461315A1 (en) *	2001-10-05	2003-04-17	Coley Pharmaceutical Gmbh	Toll-like receptor 3 signaling agonists and antagonists
AU2002360278A1 (en) *	2001-10-12	2003-11-11	Coley Pharmaceutical Gmbh	Methods and products for enhancing immune responses using imidazoquinoline compounds
TW200303759A (en) *	2001-11-27	2003-09-16	Schering Corp	Methods for treating cancer
EP1450821A1 (de) *	2001-12-07	2004-09-01	Intercell AG	Immunstimulierende oligodeoxynukleotide
JP2005516917A (ja)	2001-12-12	2005-06-09	アメリカ合衆国	細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法
ES2405405T3 (es)	2001-12-17	2013-05-31	Corixa Corporation	Composiciones y procedimientos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
US8466116B2 (en)	2001-12-20	2013-06-18	The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce epithelial cell growth
US7615227B2 (en)	2001-12-20	2009-11-10	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce angiogenesis
JP5153990B2 (ja) *	2001-12-21	2013-02-27	シーエスエル、リミテッド	免疫反応性試薬およびサポニンを含有する組成物、およびその使用方法
EP1481268A4 (de) *	2002-02-07	2005-06-29	Covalent Partners Llc	Nanofilm und membranzusammensetzungen
US20040034223A1 (en) *	2002-02-07	2004-02-19	Covalent Partners, Llc.	Amphiphilic molecular modules and constructs based thereon
US8088388B2 (en) *	2002-02-14	2012-01-03	United Biomedical, Inc.	Stabilized synthetic immunogen delivery system
WO2003070909A2 (en)	2002-02-20	2003-08-28	Chiron Corporation	Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en) *	2002-02-21	2008-04-01	Lorantis, Limited	Stabilized HBc chimer particles as immunogens for chronic hepatitis
EP2258712A3 (de) *	2002-03-15	2011-05-04	Multicell Immunotherapeutics, Inc.	Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
US20070037769A1 (en) *	2003-03-14	2007-02-15	Multicell Immunotherapeutics, Inc.	Compositions and methods to treat and control tumors by loading antigen presenting cells
WO2003078595A2 (en) *	2002-03-15	2003-09-25	Astral, Inc.	Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
IL164354A0 (en)	2002-04-04	2005-12-18	Coley Pharm Gmbh	Immunostimulatory g,u-containing oligoribonucleotides
US20030224013A1 (en) *	2002-04-19	2003-12-04	Cole Garry T.	Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
US20040009944A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Methylated immunostimulatory oligonucleotides and methods of using the same
AU2003229434A1 (en) *	2002-05-10	2003-11-11	Inex Pharmaceuticals Corporation	Cancer vaccines and methods of using the same
US20040009943A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Pathogen vaccines and methods for using the same
US20040013649A1 (en) *	2002-05-10	2004-01-22	Inex Pharmaceuticals Corporation	Cancer vaccines and methods of using the same
KR100456681B1 (ko) *	2002-05-22	2004-11-10	주식회사 대웅	박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
CA2388049A1 (en) *	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
SE0201701D0 (sv) *	2002-06-05	2002-06-05	Gotovax Ab	Treatment of epithelial tumors and infections
AU2003243409A1 (en) *	2002-06-05	2003-12-22	Coley Pharmaceutical Group, Inc.	Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
EP1513552B1 (de) *	2002-06-20	2010-12-01	Cytos Biotechnology AG	Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung
WO2004002500A1 (en)	2002-06-28	2004-01-08	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
US7605138B2 (en) *	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en)	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) *	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
DE10229872A1 (de)	2002-07-03	2004-01-29	Curevac Gmbh	Immunstimulation durch chemisch modifizierte RNA
AU2003255969A1 (en) *	2002-07-17	2004-02-02	Coley Pharmaceutical Gmbh	Use of cpg nucleic acids in prion-disease
DE60324678D1 (de)	2002-07-18	2008-12-24	Univ Washington	N t-lymphozyten und damit identifizierte hsv-antigene
EP1523557A2 (de)	2002-07-24	2005-04-20	Intercell AG	Bei alternativen leserahmen kodiertete antigenen aus pathogenischen viren
KR20050039839A (ko)	2002-08-02	2005-04-29	글락소스미스클라인 바이오로지칼즈 에스.에이.	Ｌｇｔｂ- 나이세리아 메닌기티디스로부터의 ｌ2 및/또는ｌ3 면역유형 리포올리고사카라이드를 포함하는 백신 조성물
CN1671412B (zh)	2002-08-15	2010-05-26	3M创新有限公司	免疫刺激组合物及刺激免疫反应的方法
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
GB0220194D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Improved vesicles
JP2006504687A (ja)	2002-09-13	2006-02-09	インターツェル・アクチェンゲゼルシャフト	Ｃ型肝炎ウイルスペプチドの単離方法
US20040106741A1 (en) *	2002-09-17	2004-06-03	Kriesel Joshua W.	Nanofilm compositions with polymeric components
US8263091B2 (en) *	2002-09-18	2012-09-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
AU2003268737A1 (en) *	2002-10-02	2004-04-23	Mochida Pharmaceutical Co., Ltd.	Novel method of constructing monoclonal antibody
US8043622B2 (en)	2002-10-08	2011-10-25	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
EP1551869A2 (de)	2002-10-15	2005-07-13	Intercell AG	Bindungdsfaktoren von gruppe b-streptococcus, dafür kodierende nukleinsäuren und verwendungen davon
EP2277533B1 (de)	2002-10-23	2016-07-20	GlaxoSmithKline Biologicals S.A.	Malaria-Impfverfahren
EP1578459A3 (de) *	2002-10-25	2005-11-23	University of Connecticut Health Center	Gerät und verfahren für die immuntherapie von krebs durch kontrollierte zelllyse
DK2241325T3 (da) *	2002-10-29	2012-04-10	Coley Pharm Group Inc	Anvendelse af CPG-oligonukleotider til behandling af Hepatitis Cvirusinfektion
WO2004098491A2 (en) *	2002-11-01	2004-11-18	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
WO2004046177A2 (en)	2002-11-15	2004-06-03	Chiron Srl	Unexpected surface proteins in neisseria meningitidis
WO2004047734A2 (en) *	2002-11-21	2004-06-10	Bayhill Therapeutics, Inc.	Methods and immune modulatory nucleic acid compositions for preventing and treating disease
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
JP2006512927A (ja) *	2002-12-11	2006-04-20	コーリーファーマシューティカルグループ，インコーポレイテッド	５’ｃｐｇ核酸およびその使用方法
WO2004052293A2 (en) *	2002-12-11	2004-06-24	Hawaii Biotech, Inc.	Recombinant vaccine against flavivirus infection
US20050287170A1 (en) *	2002-12-11	2005-12-29	Hawaii Biotech, Inc.	Subunit vaccine against West Nile viral infection
KR100525321B1 (ko) *	2002-12-13	2005-11-02	안웅식	파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
DE60329223D1 (de) *	2002-12-23	2009-10-22	Dynavax Tech Corp	Oligonukleotide mit einer immunsystemstimulierenden sequenz und verfahren zu deren anwendung
EP1625140A4 (de) *	2002-12-23	2008-06-18	Dynavax Tech Corp	Verzweigte immunmodulatorische verbindungen und anwendungsverfahren dafür
US8034378B2 (en)	2002-12-27	2011-10-11	Novartis Vaccines And Diagnostics, Inc	Immunogenic compositions containing phospholipid
EP2572715A1 (de)	2002-12-30	2013-03-27	3M Innovative Properties Company	Immunstimulatorische Kombinationen
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
ES2639812T3 (es)	2003-01-06	2017-10-30	Corixa Corporation	Ciertos compuestos de fosfato de aminoalquil glucosaminida y sus usos
EP2192172B1 (de)	2003-02-03	2014-12-03	iBio, Inc.	System zur Expression von Genen in Pflanzen
JP2006517974A (ja) *	2003-02-13	2006-08-03	スリーエムイノベイティブプロパティズカンパニー	Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物
US8877204B2 (en)	2003-02-20	2014-11-04	University Of Connecticut Health Center	Methods and compositions for the treatment of cancer and infectious disease using alpha (2) macroglobulin-antigenic molecule complexes
GB2398783A (en)	2003-02-26	2004-09-01	Antonio Lanzavecchia	A method for producing immortalised human B memory lymphocytes
WO2004075865A2 (en) *	2003-02-27	2004-09-10	3M Innovative Properties Company	Selective modulation of tlr-mediated biological activity
ATE441715T1 (de)	2003-03-04	2009-09-15	Intercell Ag	Streptococcus pyogenes antigene
EP1601365A4 (de)	2003-03-04	2009-11-11	3M Innovative Properties Co	Prophylaktische behandlung von uv-induzierter epidermaler neoplasie
KR20050109562A (ko) *	2003-03-13	2005-11-21	쓰리엠 이노베이티브 프로퍼티즈 컴파니	피부의 질을 개선시키는 방법
US7179253B2 (en)	2003-03-13	2007-02-20	3M Innovative Properties Company	Method of tattoo removal
ATE485056T1 (de)	2003-03-24	2010-11-15	Intercell Ag	Verbesserte impfstoffe
US20040192585A1 (en)	2003-03-25	2004-09-30	3M Innovative Properties Company	Treatment for basal cell carcinoma
EP1605972A2 (de) *	2003-03-26	2005-12-21	Cytos Biotechnology AG	Hiv-peptid-träger-konjugate
CA2520181A1 (en) *	2003-03-26	2004-10-14	Astral Inc.	Selected rna motifs to include cell death and/or apoptosis
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
US7628994B2 (en)	2003-03-31	2009-12-08	Intercell Ag	S. epidermidis antigens
CA2521050A1 (en) *	2003-04-02	2004-10-14	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
US20040265351A1 (en) *	2003-04-10	2004-12-30	Miller Richard L.	Methods and compositions for enhancing immune response
CA2521682A1 (en) *	2003-04-10	2004-12-16	3M Innovative Properties Company	Delivery of immune response modifier compounds using metal-containing particulate support materials
SE0301109D0 (sv) *	2003-04-14	2003-04-14	Mallen Huang	Nucleotide vaccine composition
EP2311988A1 (de)	2003-04-15	2011-04-20	Intercell AG	S. pneumoniae-Antigene
EP1617845A4 (de) *	2003-04-28	2006-09-20	3M Innovative Properties Co	Zusammensetzungen und verfahren zur induktion von opioid-rezeptoren
WO2004099242A2 (en)	2003-05-07	2004-11-18	Intercell Ag	Streptococcus agalactiae antigens i + ii
AU2004238139B2 (en)	2003-05-15	2009-12-03	Japan Science And Technology Agency	Immunostimulating Agents
ES2427641T3 (es)	2003-05-22	2013-10-31	Ibio, Inc.	Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana
EP2267006A1 (de)	2003-05-30	2010-12-29	Intercell AG	Enterokokken-Antigene
EP1631264B8 (de)	2003-06-02	2017-05-24	GlaxoSmithKline Biologicals SA	Immunogene, auf mikropartikel basierende zusammensetzungen, die aus einem adsorbierten toxoid und einem polysaccharid enthaltenden antigen bestehen
WO2005000884A1 (en)	2003-06-05	2005-01-06	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
AU2004257149A1 (en) *	2003-06-20	2005-01-27	Coley Pharmaceutical Gmbh	Small molecule toll-like receptor (TLR) antagonists
AU2004255470B2 (en) *	2003-07-10	2010-08-19	Cytos Biotechnology Ag	Packaged virus-like particles
US20050013812A1 (en) *	2003-07-14	2005-01-20	Dow Steven W.	Vaccines using pattern recognition receptor-ligand:lipid complexes
AU2004264330A1 (en) *	2003-08-05	2005-02-24	3M Innovative Properties Company	Infection prophylaxis using immune response modifier compounds
CA2535117A1 (en) *	2003-08-12	2005-03-03	3M Innovative Properties Company	Oxime substituted imidazo-containing compounds
US20060035242A1 (en)	2004-08-13	2006-02-16	Michelitsch Melissa D	Prion-specific peptide reagents
JP2007504145A (ja) *	2003-08-25	2007-03-01	スリーエムイノベイティブプロパティズカンパニー	免疫刺激性の組み合わせおよび治療
MY145983A (en) *	2003-08-27	2012-05-31	3M Innovative Properties Co	Aryloxy and arylalkyleneoxy substituted imidazoquinolines
JP2007504172A (ja) *	2003-09-02	2007-03-01	スリーエムイノベイティブプロパティズカンパニー	粘膜に関連した症状の処置に関する方法
JP2007504269A (ja) *	2003-09-05	2007-03-01	スリーエムイノベイティブプロパティズカンパニー	Ｃｄ５＋ｂ細胞リンパ腫の治療方法
EP2289547B1 (de)	2003-09-12	2015-12-16	Agenus Inc.	Impfstoff zur Behandlung und Prävention der Herpes Simplex-Virusinfektion
JP4989225B2 (ja) *	2003-09-25	2012-08-01	コーリーファーマシューティカルグループ，インコーポレイテッド	核酸親油性接合体
ES2346314T3 (es)	2003-10-02	2010-10-14	Glaxosmithkline Biolog Sa	Antigenos de b. pertussis y uso de los mismos en vacunacion.
US20090075980A1 (en) *	2003-10-03	2009-03-19	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and Analogs Thereof
US8871782B2 (en) *	2003-10-03	2014-10-28	3M Innovative Properties Company	Alkoxy substituted imidazoquinolines
US7544697B2 (en) *	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
JP2007509040A (ja) *	2003-10-11	2007-04-12	イネックスファーマシューティカルズコーポレイション	先天性免疫及び抗体依存性細胞傷害を強化するための方法及び組成物
BRPI0416079A (pt) *	2003-10-30	2007-01-02	Coley Pharm Gmbh	análogos de oligonucleotìdeos de classe c com uma potência imunoestimuladora aumentada
JP2007509987A (ja) *	2003-10-31	2007-04-19	スリーエムイノベイティブプロパティズカンパニー	免疫応答調節剤化合物による好中球活性化
US20050239733A1 (en) *	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) *	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
AU2004291122A1 (en) *	2003-11-14	2005-06-02	3M Innovative Properties Company	Hydroxylamine substituted imidazo ring compounds
AU2004291101A1 (en)	2003-11-14	2005-06-02	3M Innovative Properties Company	Oxime substituted imidazo ring compounds
EP1687307B1 (de) *	2003-11-25	2016-01-06	3M Innovative Properties Company	Substituierte imidazoringsysteme und verfahren
US20050287118A1 (en) *	2003-11-26	2005-12-29	Epitomics, Inc.	Bacterial plasmid with immunological adjuvant function and uses thereof
US20050277127A1 (en) *	2003-11-26	2005-12-15	Epitomics, Inc.	High-throughput method of DNA immunogen preparation and immunization
US20050226878A1 (en) *	2003-12-02	2005-10-13	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
US8940755B2 (en) *	2003-12-02	2015-01-27	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
AU2004308964B2 (en)	2003-12-23	2010-09-16	Arbor Vita Corporation	Antibodies for oncogenic strains of HPV and methods of their use
JP4817599B2 (ja) *	2003-12-25	2011-11-16	独立行政法人科学技術振興機構	免疫活性増強剤とこれを用いた免疫活性の増強方法
US8802853B2 (en) *	2003-12-29	2014-08-12	3M Innovative Properties Company	Arylalkenyl and arylalkynyl substituted imidazoquinolines
AU2004312508A1 (en) *	2003-12-30	2005-07-21	3M Innovative Properties Company	Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
WO2005067500A2 (en) *	2003-12-30	2005-07-28	3M Innovative Properties Company	Enhancement of immune responses
US7973016B2 (en) *	2004-01-23	2011-07-05	Joslin Diebetes Center	Methods of treating, reducing, or preventing autoimmune conditions
CA2555274A1 (en)	2004-02-05	2005-08-25	The Ohio State University Research Foundation	Chimeric vegf peptides
US20050181035A1 (en) *	2004-02-17	2005-08-18	Dow Steven W.	Systemic immune activation method using non CpG nucleic acids
WO2005097993A2 (en) *	2004-02-19	2005-10-20	Coley Pharmaceutical Group, Inc.	Immunostimulatory viral rna oligonucleotides
EP1734975B1 (de)	2004-03-19	2015-06-10	Herbs Spring, LLC	Pflanzliche therapie zur behandlung von nahrungsmittelallergien
TW200612932A (en) *	2004-03-24	2006-05-01	3M Innovative Properties Co	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
TWI235440B (en) *	2004-03-31	2005-07-01	Advanced Semiconductor Eng	Method for making leadless semiconductor package
JP2007532572A (ja) *	2004-04-09	2007-11-15	スリーエムイノベイティブプロパティズカンパニー	免疫反応調整剤を送達させるための方法、組成物および調製物
BRPI0510430A (pt) *	2004-04-28	2007-10-30	3M Innovative Properties Co	composições e métodos para vacinação mucosal
CN1989439B (zh)	2004-05-06	2010-12-29	美国政府健康及人类服务部	治疗葡萄膜炎的方法以及组合物
CA2837748C (en)	2004-05-25	2016-03-08	Oregon Health And Science University	Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
US20050267145A1 (en) *	2004-05-28	2005-12-01	Merrill Bryon A	Treatment for lung cancer
PT1765310E (pt)	2004-05-28	2016-03-01	Oryxe	Uma mistura para entrega transdérmica de compostos de baixo e alto peso molecular
US8017779B2 (en) *	2004-06-15	2011-09-13	3M Innovative Properties Company	Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006065280A2 (en) *	2004-06-18	2006-06-22	3M Innovative Properties Company	Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006038923A2 (en) *	2004-06-18	2006-04-13	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
US20070259881A1 (en) *	2004-06-18	2007-11-08	Dellaria Joseph F Jr	Substituted Imidazo Ring Systems and Methods
US8026366B2 (en) *	2004-06-18	2011-09-27	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
EP1781325A2 (de) *	2004-07-18	2007-05-09	CSL Limited	Immunstimulierender komplex und oligonucleotidformulierungen zur induzierung verbesserter interferon-gamma-antworten
JP5130044B2 (ja)	2004-08-03	2013-01-30	イナート・ファルマ	４ｉｇ−ｂ７−ｈ３およびその対応するｎｋ細胞受容体を標的化する治療および診断方法ならびに組成物
GB0417494D0 (en)	2004-08-05	2004-09-08	Glaxosmithkline Biolog Sa	Vaccine
US20060045886A1 (en) *	2004-08-27	2006-03-02	Kedl Ross M	HIV immunostimulatory compositions
US20090270443A1 (en) *	2004-09-02	2009-10-29	Doris Stoermer	1-amino imidazo-containing compounds and methods
JP2008513409A (ja)	2004-09-22	2008-05-01	グラクソスミスクラインバイオロジカルズソシエテアノニム	免疫原性組成物
ATE465173T1 (de)	2004-09-24	2010-05-15	Intercell Ag	Verändertes vp-1capsidprotein von parvovirus b19
JP2008000001A (ja) *	2004-09-30	2008-01-10	Osaka Univ	免疫刺激オリゴヌクレオチドおよびその医薬用途
US8846051B2 (en)	2004-10-08	2014-09-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention	Modulation of replicative fitness by deoptimization of synonymous codons
WO2006042254A2 (en) *	2004-10-08	2006-04-20	3M Innovative Properties Company	Adjuvant for dna vaccines
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
WO2006065549A2 (en)	2004-12-03	2006-06-22	Medical University Of Ohio	Attenuated vaccine useful for immunizations against coccidioides spp. infections
US20110070575A1 (en) *	2004-12-08	2011-03-24	Coley Pharmaceutical Group, Inc.	Immunomodulatory Compositions, Combinations and Methods
WO2006065751A2 (en) *	2004-12-13	2006-06-22	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
EP2394650A1 (de)	2004-12-30	2011-12-14	3M Innovative Properties Co.	Verwendung von Resiquimod zur Behandlung von Hautmetastasen
AU2005326708C1 (en)	2004-12-30	2012-08-30	3M Innovative Properties Company	Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
CA2592904C (en)	2004-12-30	2015-04-07	3M Innovative Properties Company	Chiral fused [1,2]imidazo[4,5-c] ring compounds
PL2682126T3 (pl)	2005-01-27	2017-07-31	Children's Hospital & Research Center At Oakland	Szczepionki pęcherzykowe oparte na GNA1870 dla szerokiego spektrum ochrony przeciwko chorobom spowodowanym przez Neisseria meningitidis
EP1844201B1 (de)	2005-02-04	2016-08-24	3M Innovative Properties Company	Wässrige gelformulierungen mit immunreaktionsmodifikatoren
CA2597587A1 (en)	2005-02-11	2006-08-17	Coley Pharmaceutical Group, Inc.	Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP1851314A2 (de) *	2005-02-24	2007-11-07	Coley Pharmaceutical Group, Inc.	Immunstimulierende oligonukleotide
GB0504436D0 (en)	2005-03-03	2005-04-06	Glaxosmithkline Biolog Sa	Vaccine
US8101345B1 (en)	2005-03-25	2012-01-24	Isis Pharmaceuticals, Inc.	Proinflammatory nucleic acids
EA201001322A1 (ru)	2005-03-31	2011-02-28	Глаксосмитклайн Байолоджикалс С.А.	Вакцины против хламидиоза
EP1869043A2 (de)	2005-04-01	2007-12-26	Coley Pharmaceutical Group, Inc.	Pyrazolopyridin-1,4-diamine und analoge davon
US7943636B2 (en)	2005-04-01	2011-05-17	3M Innovative Properties Company	1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
MX2007012488A (es) *	2005-04-08	2008-03-11	Coley Pharm Group Inc	Metodos para el tratamiento de asma exacerbado por enfermedad infecciosa.
JP2008538354A (ja) *	2005-04-08	2008-10-23	キメリクス，インコーポレイテッド	ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
JP2008535862A (ja) *	2005-04-08	2008-09-04	キメリクス，インコーポレイテッド	ポックスウイルス感染の治療のための化合物、組成物および方法
CA2605808A1 (en) *	2005-04-25	2006-11-02	3M Innovative Properties Company	Immunostimulatory compositions
EP1899467A2 (de) *	2005-04-26	2008-03-19	Coley Pharmaceutical GmbH	Modifizierte oligoribonukleotidanaloge mit verbesserter immunstimulierender aktivität
EP2457926B1 (de)	2005-04-29	2014-09-24	GlaxoSmithKline Biologicals S.A.	Neues Verfahren zur Vorbeugung oder Behandlung einer Infektion mit M. tuberculosis
AU2006257664B2 (en)	2005-06-14	2013-01-10	Protox Therapeutics Incorporated	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
AU2006261342B2 (en)	2005-06-15	2012-02-02	The Ohio State University Research Foundation	Her-2 peptides
GB0513421D0 (en)	2005-06-30	2005-08-03	Glaxosmithkline Biolog Sa	Vaccines
ES2330884T3 (es)	2005-07-01	2009-12-16	Index Pharmaceuticals Ab	Modulacion de la respuesta a los esteroides.
DE602006015963D1 (de)	2005-07-01	2010-09-16	Index Pharmaceuticals Ab	Immunstimulatorisches verfahren
EA200800268A1 (ru) *	2005-07-07	2008-06-30	Коли Фармасьютикал Груп, Инк.	КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
WO2007008904A2 (en)	2005-07-08	2007-01-18	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
EP2371381A3 (de)	2005-07-11	2012-07-18	Globeimmune, Inc.	Zusammensetzungen und Verfahren zur Auslösung einer Immunreaktion auf Escape-Mutanten bei gezielten Therapien
JP2009502207A (ja)	2005-08-03	2009-01-29	フラウンホーファーユーエスエー，インコーポレイテッド	イムノグロブリンの産生のための組成物および方法
US20100130425A1 (en)	2005-09-09	2010-05-27	Oregon Health & Science University	Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
WO2007088423A2 (en) *	2005-09-16	2007-08-09	Coley Pharmaceutical Gmbh	Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
JP2009508842A (ja) *	2005-09-16	2009-03-05	コーリーファーマシューティカルゲーエムベーハー	ヌクレオチド修飾による短鎖干渉リボ核酸（ｓｉＲＮＡ）の免疫賦活性の調節
US20070081972A1 (en) *	2005-09-30	2007-04-12	The University Of Iowa Research Foundation	Polymer-based delivery system for immunotherapy of cancer
EP1940472A1 (de)	2005-10-28	2008-07-09	Index Pharmaceuticals AB	Zusammensetzung und verfahren zur prävention, behandlung und/oder linderung einer entzündlichen erkrankung
EP1957647B1 (de)	2005-11-25	2015-03-04	Zoetis Belgium S.A.	Immunstimulierende oligoribonukleotide
ES2804472T3 (es)	2005-12-13	2021-02-08	Harvard College	Estructuras para trasplante celular
JP5484732B2 (ja)	2005-12-14	2014-05-07	サイトスバイオテクノロジーアーゲー	過敏症の治療のための免疫賦活性核酸パッケージ粒子
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
DK3017827T3 (en)	2005-12-22	2019-02-18	Glaxosmithkline Biologicals Sa	Pneumococcal polysaccharide conjugate VACCINE
WO2007082105A2 (en)	2006-01-16	2007-07-19	Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chlamydia vaccine
NZ569417A (en)	2006-01-17	2012-04-27	Arne Forsgren	A novel surface exposed haemophilus influenzae protein (protein E; pE)
EP1984405A4 (de)	2006-02-13	2010-06-30	Fraunhofer Usa Inc	Influenza-antigene, impfstoffzusammensetzungen und zugehörige verfahren
PT1991678E (pt) *	2006-02-15	2015-11-25	Adiutide Pharmaceuticals Gmbh	Composições e métodos para formulações de oligonucleótidos
EP3085373A1 (de)	2006-02-22	2016-10-26	3M Innovative Properties Company	Konjugate zur modifizierung von immunreaktionen
CA2649688A1 (en)	2006-03-14	2007-09-20	Oregon Health & Science University	Methods for detecting a mycobacterium tuberculosis infection
BRPI0710210A2 (pt)	2006-03-30	2011-05-24	Glaxomithkline Biolog S A	composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
WO2007119815A1 (ja)	2006-04-14	2007-10-25	Kyowa Hakko Kirin Co., Ltd.	Ｔｏｌｌ様受容体９作動薬
US8592566B2 (en) *	2006-05-31	2013-11-26	Toray Industries, Inc.	Immunostimulatory oligonucleotides and use thereof in pharmaceuticals
EP2392675A1 (de)	2006-06-02	2011-12-07	GlaxoSmithKline Biologicals S.A.	Verfahren zur Indentifizierung des Ansprechens bzw. Nichtansprechens eines Patienten auf eine Immuntherapie basierend auf die Differentielle Expression vom Gen IFNG
KR100906970B1 (ko)	2006-06-03	2009-07-10	주식회사 바이오씨에스	피부 면역질환에 대한 ＣｐＧ 올리고데옥시뉴클레오티드의치료학적 용도
WO2007143582A2 (en) *	2006-06-05	2007-12-13	Baylor College Of Medicine	Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
JP5275982B2 (ja)	2006-06-12	2013-08-28	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
MX2008015529A (es)	2006-06-12	2009-01-13	Cytos Biotechnology Ag	Procesos para empacar oligonucleotidos en particulas similares a virus de bacteriofagos de arn.
EP2292644A3 (de)	2006-07-07	2011-05-25	Intercell AG	Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
US8128921B2 (en) *	2006-07-11	2012-03-06	University Of Connecticut	Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US8153116B2 (en)	2006-07-11	2012-04-10	University Of Connecticut	Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
WO2008008432A2 (en) *	2006-07-12	2008-01-17	Coley Pharmaceutical Group, Inc.	Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
EP2046954A2 (de)	2006-07-31	2009-04-15	Curevac GmbH	Nukleinsäure der formel (i): gixngn, oder (ii): cixmcn, insbesondere als immunstimulierendes mittel/adjuvans
DE102006035618A1 (de) *	2006-07-31	2008-02-07	Curevac Gmbh	Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
CA2662064A1 (en)	2006-09-07	2008-03-13	Glaxosmithkline Biologicals S.A.	Method of producing a combination polivirus vaccine
CA2661224A1 (en)	2006-09-15	2008-03-20	Intercell Ag	Borrelia antigens
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
JP5443164B2 (ja)	2006-09-26	2014-03-19	インフェクティアスディジーズリサーチインスティチュート	合成アジュバントを含むワクチン組成物
PT2078080E (pt)	2006-09-27	2015-09-18	Coley Pharm Gmbh	Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
US20100144846A1 (en) *	2006-10-26	2010-06-10	Coley Pharmaceutical Gmbh	Oligoribonucleotides and uses thereof
ES2465465T3 (es)	2006-11-01	2014-06-05	Ventana Medical Systems, Inc.	Haptenos, conjugados de haptenos, composiciones de los mismos y método para su preparación y uso
WO2008057529A2 (en) *	2006-11-06	2008-05-15	Coley Pharmaceutical Group, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
WO2008073661A2 (en)	2006-11-09	2008-06-19	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
EP1923069A1 (de)	2006-11-20	2008-05-21	Intercell AG	Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
US20080149123A1 (en) *	2006-12-22	2008-06-26	Mckay William D	Particulate material dispensing hairbrush with combination bristles
WO2008084072A2 (en)	2007-01-12	2008-07-17	Intercell Ag	Protective proteins of s. agalactiae, combinations thereof and methods of using the same
EP2444410A3 (de)	2007-02-28	2012-08-08	The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services	Brachyurie-Polypeptide und Verwendungsverfahren
JP5869206B2 (ja)	2007-03-02	2016-02-24	グラクソスミスクラインバイオロジカルズソシエテアノニム	新規方法および組成物
US20090041809A1 (en) *	2007-03-07	2009-02-12	Nventa Biopharmaceuticals Corporation	Double-stranded locked nucleic acid compositions
US8501167B2 (en)	2007-03-19	2013-08-06	Globeimmune, Inc.	Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
PL2136836T3 (pl)	2007-04-04	2017-07-31	Infectious Disease Research Institute	Kompozycje immunogenne zawierające polipeptydy prątka gruźlicy i produkty ich fuzji
AR066405A1 (es)	2007-04-20	2009-08-19	Glaxosmithkline Biolog Sa	Vacuna
CA2685558A1 (en)	2007-04-28	2008-11-06	Fraunhofer Usa, Inc.	Trypanosoma antigens, vaccine compositions, and related methods
US20100074918A1 (en)	2007-05-02	2010-03-25	Jan Poolman	Vaccine
EP2152731A2 (de)	2007-05-02	2010-02-17	Intercell AG	Klebsiella-antigene
EP2573176B1 (de) *	2007-05-04	2016-04-06	InDex Pharmaceuticals AB	Tumorwachstumshemmende Verbindungen und Verfahren zu ihrer Verwendung
CN101678098A (zh)	2007-05-17	2010-03-24	科勒制药集团公司	具有免疫刺激效力的a类寡核苷酸
CA2687535C (en) *	2007-05-18	2017-08-22	Coley Pharmaceutical Gmbh	Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity
JP2010528285A (ja)	2007-05-23	2010-08-19	ベンタナ・メデイカル・システムズ・インコーポレーテツド	免疫組織化学およびｉｎｓｉｔｕハイブリダーゼーションのためのポリマー担体
EP2476431A1 (de)	2007-05-24	2012-07-18	GlaxoSmithKline Biologicals S.A.	Lyophilisierte Antigenzusammensetzung
EP2012122A1 (de)	2007-07-06	2009-01-07	Medigene AG	Strukturproteine von mutierten Parvoviren als Impfstoffe
WO2008145400A2 (en)	2007-05-31	2008-12-04	Medigene Ag	Mutated structural protein of a parvovirus
JP2010530229A (ja)	2007-06-18	2010-09-09	インターセルアーゲー	クラミジア属の抗原
CN101883583B (zh)	2007-06-26	2017-05-17	葛兰素史密丝克莱恩生物有限公司	含有肺炎链球菌荚膜多糖缀合物的疫苗
EP2170384B1 (de)	2007-07-02	2016-04-13	Etubics Corporation	Verfahren und zusammensetzungen zur herstellung eines adenovirus-vektors zur verwendung mit multiplen impfungen
WO2009009759A2 (en)	2007-07-11	2009-01-15	Fraunhofer Usa, Inc.	Yersinia pestis antigens, vaccine compositions, and related methods
KR101580660B1 (ko)	2007-08-02	2015-12-28	바이오앤드백스 파마슈티칼즈, 리미티드.	다중체 다중-에피토프 인플루엔자 백신
CN102027003A (zh)	2007-08-03	2011-04-20	哈佛大学校长及研究员协会	衣原体抗原
US7879812B2 (en)	2007-08-06	2011-02-01	University Of Iowa Research Foundation	Immunomodulatory oligonucleotides and methods of use therefor
CA2695477A1 (en)	2007-08-13	2009-02-19	Glaxosmithkline Biologicals S.A.	Infant plasmodium falciparum cs vaccines
BRPI0814899A2 (pt) *	2007-08-21	2015-02-03	Dynavax Tech Corp	Composição, vacina, metodo para amenizar um ou mais sintomas associados à infecção com o virus da influenza em um individuo e método para reduzir a probabilidade de infecção com o virus da influeza em um individuo"
US9370531B2 (en)	2007-08-31	2016-06-21	New York University	Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
WO2009030254A1 (en)	2007-09-04	2009-03-12	Curevac Gmbh	Complexes of rna and cationic peptides for transfection and for immunostimulation
EA017879B1 (ru)	2007-09-17	2013-03-29	Онкометилом Сайенсиз Са	Улучшенное определение экспрессии mage-a
CN101820908A (zh) *	2007-10-09	2010-09-01	科利制药公司	包含改性糖部分的免疫刺激寡核苷酸类似物
MX2010005022A (es)	2007-11-07	2010-06-02	Celldex Therapeutics Inc	Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
WO2010008411A1 (en)	2007-11-09	2010-01-21	The Salk Institute For Biological Studies	Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
EP2227250A4 (de)	2007-12-03	2011-07-06	Harvard College	Chlamydia-antigene
EP3067048B1 (de)	2007-12-07	2018-02-14	GlaxoSmithKline Biologicals SA	Zusammensetzungen zur induzierung von immunreaktionen
ES2597439T3 (es)	2007-12-24	2017-01-18	Id Biomedical Corporation Of Quebec	Antígenos recombinantes del VSR
WO2009094191A2 (en) *	2008-01-25	2009-07-30	Chimerix, Inc.	Methods of treating viral infections
PL2176408T3 (pl)	2008-01-31	2015-08-31	Curevac Gmbh	Kwasy nukleinowe zawierające wzór (NuGiXmGnNv)a i ich pochodne jako środki immunostymulujące/ adiuwanty
CA2715460C (en)	2008-02-13	2020-02-18	President And Fellows Of Harvard College	Continuous cell programming devices
US10383887B2 (en) *	2008-02-20	2019-08-20	New York University	Preventing and treating amyloid-beta deposition by stimulation of innate immunity
AU2009223613B2 (en)	2008-03-10	2014-09-25	Children's Hospital & Research Center At Oakland	Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
CA2718473A1 (en)	2008-03-17	2009-09-24	Intercell Ag	Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
ES2651924T3 (es)	2008-04-18	2018-01-30	The General Hospital Corporation	Inmunoterapias que emplean vacunas autoensamblantes
EP2300102B1 (de)	2008-05-15	2014-01-08	Dynavax Technologies Corporation	Immunstimulatorische Sequenzen enhaltend CpG zur Verwendung bei der Behandlung der allergischen Rhinitis
WO2009143292A2 (en)	2008-05-21	2009-11-26	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating pneumoconiosis with oligodeoxynucleotides
US9415006B2 (en)	2008-05-23	2016-08-16	The Regents Of The University Of Michigan	Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
WO2009149013A2 (en)	2008-06-05	2009-12-10	Ventana Medical Systems, Inc.	Compositions comprising nanomaterials and method for using such compositions for histochemical processes
TWI351288B (en) *	2008-07-04	2011-11-01	Univ Nat Pingtung Sci & Tech	Cpg dna adjuvant in avian vaccines
JP5689796B2 (ja)	2008-08-01	2015-03-25	ガマワクチンズピーティワイリミテッド	インフルエンザワクチン
EP2385371B1 (de)	2008-09-22	2014-10-22	Oregon Health and Science University	Verfahren zum Erkennen einer Infektion mit dem Mycobakterium tuberculosis
US8962026B2 (en)	2008-09-26	2015-02-24	The Regents Of The University Of Michigan	Nanoemulsion therapeutic compositions and methods of using the same
US8734803B2 (en)	2008-09-28	2014-05-27	Ibio Inc.	Humanized neuraminidase antibody and methods of use thereof
WO2010037408A1 (en)	2008-09-30	2010-04-08	Curevac Gmbh	Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
EP2344522B1 (de)	2008-10-16	2016-01-27	The University of Saskatchewan	Kombination-adjuvans-formulierung
WO2010048572A1 (en)	2008-10-23	2010-04-29	Cornell University	A novel anti-viral method
WO2010048731A1 (en) *	2008-10-31	2010-05-06	Christopher John Ong	Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents
WO2010057197A1 (en)	2008-11-17	2010-05-20	The Regents Of The University Of Michigan	Cancer vaccine compositions and methods of using the same
WO2010059253A2 (en)	2008-11-24	2010-05-27	Massachusets Institute Of Technology	Methods and compositions for localized agent delivery
US9394333B2 (en)	2008-12-02	2016-07-19	Wave Life Sciences Japan	Method for the synthesis of phosphorus atom modified nucleic acids
JP2012510284A (ja)	2008-12-03	2012-05-10	プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ	ワクチンの開発のためのフェノール可溶性モジュリンの使用
WO2010064243A1 (en)	2008-12-03	2010-06-10	Protea Vaccine Technologies Ltd.	GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
HUE027823T2 (hu)	2008-12-09	2016-11-28	Coley Pharm Group Inc	Immunstimuláló oligonukleotidok
EP2865389A1 (de)	2008-12-09	2015-04-29	Pfizer Vaccines LLC	IgE CH3 Peptid-Impfstoff
US8552165B2 (en) *	2008-12-09	2013-10-08	Heather Davis	Immunostimulatory oligonucleotides
US8425922B2 (en)	2009-01-05	2013-04-23	EpitoGenesis, Inc.	Adjuvant compositions and methods of use
WO2010084100A1 (en)	2009-01-20	2010-07-29	Transgene Sa	Soluble icam-1 as biomarker for prediction of therapeutic response
US20100234283A1 (en)	2009-02-04	2010-09-16	The Ohio State University Research Foundation	Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
US20130243779A1 (en)	2009-02-05	2013-09-19	Intercell Ag	Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (de)	2009-02-13	2012-01-18	Intercell AG	Nicht typisierbare haemophilus influenza-antigene
US8664183B2 (en)	2009-02-27	2014-03-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	SPANX-B polypeptides and their use
AU2010225125A1 (en)	2009-03-17	2011-10-20	Glaxosmithkline Biologicals S.A.	Improved detection of gene expression
US8530431B2 (en)	2009-03-23	2013-09-10	Pin Pharma, Inc.	Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
SG2014014021A (en)	2009-03-24	2014-07-30	Transgene Sa	Biomarker for monitoring patients
WO2010115118A2 (en)	2009-04-03	2010-10-07	Antigenics, Inc.	Methods for preparing and using multichaperone-antigen complexes
JP5661738B2 (ja)	2009-04-17	2015-01-28	トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅＳ．Ａ．	患者をモニターするためのバイオマーカー
US20110223201A1 (en) *	2009-04-21	2011-09-15	Selecta Biosciences, Inc.	Immunonanotherapeutics Providing a Th1-Biased Response
DK2424562T3 (en)	2009-04-30	2015-12-07	Coley Pharm Group Inc	Pneumococcal vaccine and uses thereof
CA2763486A1 (en)	2009-05-27	2010-12-02	Glaxosmithkline Biologicals Sa	Casb7439 constructs
AU2010254550B2 (en)	2009-05-27	2015-10-15	Selecta Biosciences, Inc.	Targeted synthetic nanocarriers with pH sensitive release of immunomodulatory agents
PL2437753T3 (pl)	2009-06-05	2017-03-31	Infectious Disease Research Institute	Syntetyczne adiuwanty glukopiranozylolipidowe oraz zawierające je kompozycje szczepionek
EP2442827B1 (de)	2009-06-16	2016-01-06	The Regents of the University of Michigan	Nanoemulsionsimpfstoffe
AU2010264686A1 (en)	2009-06-24	2012-01-19	Glaxosmithkline Biologicals S.A.	Vaccine
PL2445526T3 (pl)	2009-06-24	2017-08-31	Glaxosmithkline Biologicals S.A.	Rekombinowane antygeny rsv
RU2612521C2 (ru)	2009-07-06	2017-03-09	Онтории, Инк.	Новые пролекарства нуклеиновых кислот и способы их применения
ES2558729T3 (es)	2009-07-10	2016-02-08	Transgene Sa	Biomarcador para la selección de pacientes y procedimientos relacionados
EP2453918B1 (de)	2009-07-15	2015-12-16	GlaxoSmithKline Biologicals S.A.	Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
US8614200B2 (en)	2009-07-21	2013-12-24	Chimerix, Inc.	Compounds, compositions and methods for treating ocular conditions
WO2011013034A1 (en) *	2009-07-30	2011-02-03	Pfizer Vaccines Llc	Antigenic tau peptides and uses thereof
US20110033515A1 (en) *	2009-08-04	2011-02-10	Rst Implanted Cell Technology	Tissue contacting material
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
JP2013502456A (ja)	2009-08-26	2013-01-24	アールエヌエーアイエヌシー	リポタイコ酸由来の糖脂質及びこれを含む組成物
WO2011026111A1 (en)	2009-08-31	2011-03-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Oral delivery of a vaccine to the large intestine to induce mucosal immunity
US20110053829A1 (en)	2009-09-03	2011-03-03	Curevac Gmbh	Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
TR201808222T4 (tr)	2009-09-03	2018-07-23	Pfizer Vaccines Llc	PCSK9 aşısı.
US20110229437A1 (en) *	2009-09-17	2011-09-22	Mutual Pharmaceutical Company, Inc.	Method of Treating Asthma with Antiviral Agents
GB0917457D0 (en)	2009-10-06	2009-11-18	Glaxosmithkline Biolog Sa	Method
US8784819B2 (en)	2009-09-29	2014-07-22	Ibio Inc.	Influenza hemagglutinin antibodies, compositions and related methods
CN102782138A (zh)	2009-10-07	2012-11-14	Uvic工业合伙公司	包含热敏性转基因的疫苗
EP2308896A1 (de)	2009-10-09	2011-04-13	Sanofi-aventis	Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
PE20121689A1 (es)	2009-10-09	2012-12-14	Sanofi Sa	Polipeptidos para union al receptor para productos finales de glicosilacion avanzada asi como composiciones y metodos que implican a los mismos
EP2319871A1 (de)	2009-11-05	2011-05-11	Sanofi-aventis	Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
WO2011047340A1 (en)	2009-10-16	2011-04-21	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
GB0919117D0 (en)	2009-10-30	2009-12-16	Glaxosmithkline Biolog Sa	Process
CN102713629B (zh)	2009-11-20	2016-02-24	俄勒冈健康科学大学	用于检测结核分枝杆菌感染的方法
WO2011067758A2 (en)	2009-12-02	2011-06-09	Protea Vaccine Technologies Ltd.	Immunogenic fragments and multimers from streptococcus pneumoniae proteins
SG181628A1 (en)	2009-12-22	2012-07-30	Celldex Therapeutics Inc	Vaccine compositions
FR2954703B1 (fr)	2009-12-28	2013-12-13	Chu Nantes	Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
DK2534150T3 (en)	2010-02-12	2017-06-12	Chimerix Inc	METHODS OF TREATING VIRUS INFECTION
WO2011101332A1 (en)	2010-02-16	2011-08-25	Proyecto De Biomedicina Cima, S.L.	Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2011109422A2 (en)	2010-03-02	2011-09-09	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Compositions and methods for the treatment of cancer
US20130195919A1 (en)	2010-03-05	2013-08-01	President And Fellows Of Harvard College	Induced dendritic cell compositions and uses thereof
GB201003924D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Immunogenic composition
GB201003920D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Method of treatment
CA2792683A1 (en)	2010-03-10	2011-09-15	Glaxosmithkline Biologicals S.A.	Neisserial fhbp vaccine composition
WO2011112599A2 (en)	2010-03-12	2011-09-15	The United States Of America, As Represented By The Secretary. Department Of Health & Human Services	Immunogenic pote peptides and methods of use
EP2547327B1 (de)	2010-03-19	2018-09-05	Massachusetts Institute of Technology	Lipidvesikelzusammensetzungen und verfahren zu ihrer verwendung
US20110229556A1 (en) *	2010-03-19	2011-09-22	Massachusetts Institute Of Technology	Lipid-coated polymer particles for immune stimulation
US9149432B2 (en)	2010-03-19	2015-10-06	Massachusetts Institute Of Technology	Lipid vesicle compositions and methods of use
GB201005005D0 (en) *	2010-03-25	2010-05-12	Angeletti P Ist Richerche Bio	New vaccine
EP2552942B1 (de)	2010-03-30	2017-12-27	Children's Hospital & Research Center at Oakland	Faktor-h-bindende proteine (fhbp) mit geänderten eigenschaften und verwendungsverfahren dafür
AU2011239706B2 (en)	2010-04-13	2015-08-20	Celldex Therapeutics Inc.	Antibodies that bind human CD27 and uses thereof
US9278135B2 (en)	2010-04-26	2016-03-08	Chimerix Inc.	Methods of treating retroviral infections and related dosage regimes
PT2569436T (pt)	2010-05-14	2018-03-05	Univ Oregon Health & Science	Vectores de hcmv e rhcmv recombinantes e seus usos
CN102905729A (zh)	2010-05-26	2013-01-30	西莱克塔生物科技公司	含有佐剂的合成纳米载体的剂量选择
CA2800158C (en) *	2010-05-28	2020-07-21	Coley Pharmaceutical Group, Inc.	Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
WO2011154878A1 (en)	2010-06-07	2011-12-15	Pfizer Vaccines Llc	Ige ch3 peptide vaccine
US8658603B2 (en)	2010-06-16	2014-02-25	The Regents Of The University Of Michigan	Compositions and methods for inducing an immune response
CA2801523C (en)	2010-07-30	2021-08-03	Curevac Gmbh	Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
LT2753352T (lt)	2010-09-03	2017-05-25	Valneva Austria Gmbh	Išskirtas toksino a ir toksino b baltymų polipeptidas iš c. difficile ir jo panaudojimas
WO2012031760A1 (en)	2010-09-08	2012-03-15	Medigene Ag	Parvovirus mutated structural proteins comprising cross - protective b - cell epitopes of a hpv l2 protein as well as products and methods relating thereto
GB201015132D0 (en)	2010-09-10	2010-10-27	Univ Bristol	Vaccine composition
EP2616545B1 (de)	2010-09-14	2018-08-29	University of Pittsburgh - Of the Commonwealth System of Higher Education	Rechnerisch optimierte breit reaktive influenza-antigene
EP2620428B1 (de)	2010-09-24	2019-05-22	Wave Life Sciences Ltd.	Asymmetrische hilfsgruppe
CA2809463C (en)	2010-09-27	2021-05-25	Crucell Holland B.V.	Heterologous prime boost vaccination regimen against malaria
PT2624873T (pt)	2010-10-06	2020-03-04	Harvard College	Hidrogéis injectáveis formadores de poros para terapias celulares à base de materiais
WO2012057904A1 (en)	2010-10-27	2012-05-03	Infectious Disease Research Institute	Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
US9994443B2 (en)	2010-11-05	2018-06-12	Selecta Biosciences, Inc.	Modified nicotinic compounds and related methods
WO2012064659A1 (en)	2010-11-08	2012-05-18	Infectious Disease Research Institute	Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
RS54687B1 (en)	2010-12-14	2016-08-31	Glaxosmithkline Biologicals S.A.	COMPOSITION OF MYCOBACTERIAL ANTIGENS
EP2667891B1 (de)	2011-01-27	2021-10-06	Gamma Vaccines Pty Limited	Kombinationsimpfstoffe
CA2828068C (en)	2011-02-22	2019-03-19	Biondvax Pharmaceuticals Ltd.	Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2012131504A1 (en)	2011-03-02	2012-10-04	Pfizer Inc.	Pcsk9 vaccine
EP2505640A1 (de)	2011-03-29	2012-10-03	Neo Virnatech, S.L.	Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
GB201106357D0 (en)	2011-04-14	2011-06-01	Pessi Antonello	Composition and uses thereof
NZ616304A (en)	2011-04-08	2016-01-29	Immune Design Corp	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TW201302779A (zh)	2011-04-13	2013-01-16	Glaxosmithkline Biolog Sa	融合蛋白質及組合疫苗
US20120288515A1 (en)	2011-04-27	2012-11-15	Immune Design Corp.	Synthetic long peptide (slp)-based vaccines
SI2707385T1 (en)	2011-05-13	2018-01-31	Glaxosmithkline Biologicals Sa	Pregnant RSV F antigens
FR2975600B1 (fr)	2011-05-24	2013-07-05	Assist Publ Hopitaux De Paris	Agents pour le traitement de tumeurs
EP2713737B1 (de)	2011-06-01	2016-04-20	Janus Biotherapeutics, Inc.	Neue immunsystemmodulatoren
RU2606114C2 (ru)	2011-06-01	2017-01-10	Джейнус Байотерапьютикс, Инк.	Новые модуляторы иммунной системы
BR112013031039B1 (pt)	2011-06-03	2020-04-28	3M Innovative Properties Co	compostos de hidrazino 1h-imidazoquinolina-4-aminas, conjugados feitos destes compostos, composição e composição farmacêutica compreendendo ditos compostos e conjugados, usos dos mesmos e método de fabricação do conjugado
BR112013031028A2 (pt)	2011-06-03	2016-11-29	3M Innovative Properties Co	conectores heterobifuncionais com segmentos de polietileno glicol e conjugados de modificadores de resposta imunológica feitos a partir deles
EP2717909B1 (de)	2011-06-04	2017-12-06	Rochester General Hospital Research Institute	Zusammensetzungen und verfahren in zusammenhang mit p6 von haemophilus influenzae
EP2718444B1 (de)	2011-06-07	2017-12-27	iBio, Inc.	In-vivo-deglycosylierung rekombinanter proteine durch co-expression mit pngase f
EP2720706B1 (de)	2011-06-17	2020-08-05	University of Tennessee Research Foundation	Polyvalenter streptococcus-gruppe-a-impfstoff
BR112013032723A2 (pt)	2011-06-20	2017-01-31	Univ Pittsburgh Commonwealth Sys Higher Education	antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
WO2012177595A1 (en)	2011-06-21	2012-12-27	Oncofactor Corporation	Compositions and methods for the therapy and diagnosis of cancer
WO2013007703A1 (en) *	2011-07-08	2013-01-17	Universität Zürich	CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS
JP6128529B2 (ja)	2011-07-19	2017-05-17	ウェイブライフサイエンシズリミテッドＷａｖｅＬｉｆｅＳｃｉｅｎｃｅｓＬｔｄ．	官能化核酸の合成のための方法
US20130023736A1 (en)	2011-07-21	2013-01-24	Stanley Dale Harpstead	Systems for drug delivery and monitoring
CN109172819A (zh)	2011-07-29	2019-01-11	西莱克塔生物科技公司	产生体液和细胞毒性t淋巴细胞（ctl）免疫应答的合成纳米载体
GB201114919D0 (en)	2011-08-30	2011-10-12	Glaxosmithkline Biolog Sa	Method
WO2013039792A1 (en)	2011-09-12	2013-03-21	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Immunogens based on an hiv-1 gp120 v1v2 epitope
WO2013038156A1 (en)	2011-09-16	2013-03-21	Ucb Pharma S.A.	Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
ES2548391T3 (es)	2011-09-21	2015-10-16	Ruprecht-Karls-Universität Heidelberg	Péptidos de cambio de marco (FSP) específicos de MSI para prevención y tratamiento del cáncer
US20140234360A1 (en)	2011-09-30	2014-08-21	The United States of America, as represented by the Secretary, Dept.of Health and Human Services	Influenza vaccine
AU2012318694B2 (en)	2011-10-04	2016-12-22	Janus Biotherapeutics, Inc.	Novel imidazole quinoline-based immune system modulators
EP2768847A4 (de)	2011-10-20	2015-11-11	Us Gov Health & Human Serv	E-glycoprotein-polypeptide des dengue-virus mit mutationen zur eliminierung von immundominanten kreuzreaktiven epitopen
WO2013074501A1 (en)	2011-11-14	2013-05-23	Crucell Holland B.V.	Heterologous prime-boost immunization using measles virus-based vaccines
EP2596806A1 (de)	2011-11-25	2013-05-29	Index Pharmaceuticals AB	Verfahren zur Vorbeugung einer Dickdarmresektion
US12268718B2 (en)	2012-01-16	2025-04-08	Labyrinth Holdings Llc	Control of cellular redox levels
CN104144693A (zh)	2012-01-16	2014-11-12	E·麦肯纳	用于治疗肝脏疾病和障碍的组合物和方法
WO2013113326A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
TR201908003T4 (tr)	2012-02-07	2019-06-21	Infectious Disease Res Inst	TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
SG11201404653UA (en)	2012-02-07	2014-09-26	Univ Pittsburgh	Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
JP6175452B2 (ja)	2012-02-13	2017-08-02	ユニバーシティオブピッツバーグ − オブザコモンウェルスシステムオブハイヤーエデュケイション	ヒトおよびトリｈ５ｎ１インフルエンザのための、計算で最適化した反応性の広い抗原
WO2013142808A1 (en)	2012-03-23	2013-09-26	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pathogenic phlebovirus isolates and compositions and methods of use
WO2013150518A1 (en)	2012-04-01	2013-10-10	Rappaport Family Institute For Research In The Medical Sciences	Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
ES2773895T3 (es)	2012-04-16	2020-07-15	Harvard College	Composiciones de sílice mesoporosa para modular las respuestas inmunitarias
WO2013163176A1 (en)	2012-04-23	2013-10-31	Allertein Therapeutics, Llc	Nanoparticles for treatment of allergy
CA2871711A1 (en)	2012-05-04	2013-11-07	Pfizer Inc.	Prostate-associated antigens and vaccine-based immunotherapy regimens
PT2850431T (pt)	2012-05-16	2018-07-23	Immune Design Corp	Vacinas para hsv-2
EP2666785A1 (de)	2012-05-23	2013-11-27	Affiris AG	Auf Komplementfaktor C5a basierender Impfstoff
CN104470537B (zh)	2012-05-23	2017-04-26	美国政府(由卫生和人类服务部的部长所代表)	表达鼠疫耶尔森氏菌F1‑V融合蛋白的伤寒沙门氏菌Ty21a及其用途
WO2013177397A1 (en)	2012-05-24	2013-11-28	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Multivalent meningococcal conjugates and methods for preparing cojugates
US9687542B2 (en)	2012-06-19	2017-06-27	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Rift valley fever virus replicon particles and use thereof
CN104684893B (zh)	2012-07-13	2016-10-26	日本波涛生命科学公司	不对称辅助基团
WO2014012081A2 (en)	2012-07-13	2014-01-16	Ontorii, Inc.	Chiral control
KR101835401B1 (ko)	2012-07-13	2018-03-08	신 니뽄 바이오메디칼 라보라토리즈, 엘티디.	키랄 핵산 어쥬번트
BR112015002483A2 (pt)	2012-08-03	2017-11-07	Infectious Disease Res Inst	composições e métodos para o tratamento de uma infecção ativa por mycobacterium tuberculosis
SG11201500573RA (en)	2012-08-06	2015-02-27	Glaxosmithkline Biolog Sa	Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en)	2012-08-06	2014-02-06	Glaxosmithkline Biologicals, S.A.	Novel method
WO2014031178A1 (en)	2012-08-24	2014-02-27	Etubics Corporation	Replication defective adenovirus vector in vaccination
EP2703483A1 (de)	2012-08-29	2014-03-05	Affiris AG	PCSK9 Peptidimpfstoff
US10973892B2 (en)	2012-09-04	2021-04-13	Bavarian Nordic A/S	Methods and compositions for enhancing vaccine immune responses
WO2014043535A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions for the treatment of cancer
EP2895191B1 (de)	2012-09-14	2019-06-05	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Brachyury-protein, adenovirale vektoren zur codierung von brachyury-protein und deren verwendung
US10232035B2 (en)	2012-09-14	2019-03-19	The Regents Of The University Of Colorado, A Body Corporate	Conditionally replication deficient herpes virus and use thereof in vaccines
EP2898073A4 (de)	2012-09-21	2016-03-23	Elizabeth Mckenna	Natürlich vorkommende cpg-oligonukleotidzusammensetzungen und therapeutische anwendungen davon
JP2016501515A (ja)	2012-10-24	2016-01-21	プレートレットターゲテッドセラピューティクス，エルエルシー	血小板標的化治療
WO2014090265A1 (en)	2012-12-13	2014-06-19	Ruprecht-Karls-Universität Heidelberg	Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer
AU2014203896B2 (en)	2013-01-07	2018-05-31	The Trustees Of The University Of Pennsylvania	Compositions and methods for treating cutaneous T cell lymphoma
WO2014116730A2 (en)	2013-01-23	2014-07-31	The Board Of Trustees Of The Leland Stanford Junior University	Stabilized hepatitis b core polypeptide
KR102450375B1 (ko)	2013-03-13	2022-10-04	더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈	선융합(prefusion) RSV F 단백질 및 이의 용도
ES2924914T3 (es)	2013-03-15	2022-10-11	Glaxosmithkline Biologicals Sa	Vacuna contra rinovirus humano
ES2728865T3 (es)	2013-03-28	2019-10-29	Infectious Disease Res Inst	Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
CA2907915C (en)	2013-04-03	2023-03-07	Allertein Therapeutics, Llc	Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
US8957047B2 (en)	2013-04-18	2015-02-17	Immune Design Corp.	GLA monotherapy for use in cancer treatment
CA2909721A1 (en)	2013-04-19	2014-10-23	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Lone star virus
CA2909586C (en)	2013-05-15	2021-08-31	The Governors Of The University Of Alberta	E1e2 hcv vaccines and methods of use
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en)	2013-06-05	2013-07-17	Glaxosmithkline Biolog Sa	Immunogenic composition for use in therapy
WO2014201245A1 (en)	2013-06-12	2014-12-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
CN105579582A (zh)	2013-07-25	2016-05-11	埃克西奎雷股份有限公司	用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
EP3632458B1 (de)	2013-07-26	2025-03-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Verbindungen und pharmazeutische zusammensetzungen zur behandlung von bakterieninfektionen
WO2015018806A1 (en)	2013-08-05	2015-02-12	Glaxosmithkline Biologicals S.A.	Combination immunogenic compositions
CN105473158B (zh)	2013-08-21	2021-04-13	库瑞瓦格股份公司	呼吸道合胞病毒(rsv)疫苗
WO2015048498A2 (en)	2013-09-27	2015-04-02	Massachusetts Institute Of Technology	Carrier-free biologically-active protein nanostructures
US10010606B2 (en)	2013-09-30	2018-07-03	Los Alamos National Security, Llc	Mosaic conserved region HIV immunogenic polypeptides
JP2016533352A (ja)	2013-10-04	2016-10-27	ピーアイエヌファーマインコーポレイテッド	免疫刺激性ＨＩＶＴａｔ誘導体ポリペプチドによる癌の治療
CA2928700C (en)	2013-11-01	2019-01-15	University Of Oslo	Albumin variants and uses thereof
RU2650860C2 (ru)	2013-11-01	2018-04-17	Пфайзер Инк.	Векторы для экспрессии простатоассоциированных антигенов
US10357554B2 (en)	2013-11-11	2019-07-23	The United States Of America, As Represented By The Secretary Of The Army	AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
WO2015071769A2 (en)	2013-11-13	2015-05-21	University Of Oslo	Outer membrane vesicles and uses thereof
WO2015071763A2 (en)	2013-11-15	2015-05-21	Oslo Universitetssykehus Hf	Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
AU2014352986A1 (en)	2013-11-20	2016-06-16	Alk-Abello A/S	Pan pollen immunogens and methods and uses thereof for immune response modulation
WO2015077442A2 (en)	2013-11-20	2015-05-28	La Jolla Institute For Allergy And Immunology	Grass pollen immunogens and methods and uses for immune response modulation
CN105829537B (zh)	2013-11-28	2020-09-22	巴法里安诺迪克有限公司	用于使用痘病毒载体诱导增强的免疫应答的组合物和方法载体
EP3079716B1 (de)	2013-12-13	2019-05-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Multi-epitop tarp-peptid-impfstoff und seine verwendungen
WO2015092710A1 (en)	2013-12-19	2015-06-25	Glaxosmithkline Biologicals, S.A.	Contralateral co-administration of vaccines
CN106163551A (zh)	2013-12-31	2016-11-23	传染性疾病研究院	单瓶疫苗制剂
JPWO2015108046A1 (ja) *	2014-01-15	2017-03-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
US10149905B2 (en)	2014-01-15	2018-12-11	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
WO2015108047A1 (ja) *	2014-01-15	2015-07-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
EP3094728B1 (de)	2014-01-16	2022-03-09	Wave Life Sciences Ltd.	Chirales design
US11160855B2 (en)	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2015209575A1 (en)	2014-01-21	2016-07-21	Immune Design Corp.	Compositions for use in the treatment of allergic conditions
HUE055408T2 (hu)	2014-01-21	2021-12-28	Pfizer	Streptococcus pneumoniae kapszuláris poliszacharidok és konjugátumaik
HUE064837T2 (hu)	2014-01-21	2024-05-28	Pfizer	Streptococcus pneumoniae kapszuláris poliszacharidok és azok konjugátumai
WO2015110941A2 (en)	2014-01-21	2015-07-30	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2015123291A1 (en)	2014-02-11	2015-08-20	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Pcsk9 vaccine and methods of using the same
TW201620927A (zh)	2014-02-24	2016-06-16	葛蘭素史密斯克藍生物品公司	Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (en)	2014-02-28	2015-09-03	Alk-Abelló A/S	Polypeptides derived from phl p and methods and uses thereof for immune response modulation
US10369216B2 (en)	2014-04-01	2019-08-06	Curevac Ag	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
WO2015164798A1 (en)	2014-04-25	2015-10-29	Tria Bioscience Corp.	Synthetic hapten carrier compositions and methods
WO2015168379A2 (en)	2014-04-30	2015-11-05	President And Fellows Of Harvard College	Combination vaccine devices and methods of killing cancer cells
WO2015184272A2 (en)	2014-05-30	2015-12-03	Sanofi Pasteur Biologics Llc	Expression and conformational analysis of engineered influenza hemagglutinin
ES2725948T3 (es)	2014-06-04	2019-09-30	Exicure Inc	Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas
EP2952893A1 (de)	2014-06-04	2015-12-09	Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)	Verfahren zur Erkennung von antikörpersezernierenden, HLA-spezifischen B-Zellen
BR112016028816A8 (pt)	2014-06-13	2021-07-20	Glaxosmithkline Biologicals Sa	combinação imunogênica, método para obter uma resposta imunológica específica, uso de uma combinação imunogênica, e, regime de vacinação para prevenção, redução ou tratamento de infecção por vírus sincicial respiratório
CA2955015A1 (en)	2014-07-15	2016-01-21	Immune Design Corp.	Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
JP6820830B2 (ja)	2014-07-18	2021-01-27	ユニヴァーシティオブワシントン	がんワクチン組成物およびその使用方法
AR101256A1 (es)	2014-07-21	2016-12-07	Sanofi Pasteur	Composición vacunal que comprende ipv y ciclodextrinas
JP2017525711A (ja)	2014-08-22	2017-09-07	ジャナスバイオセラピューティクス，インク．	新規なｎ２，ｎ４，ｎ７，６−四置換プテリジン−２，４，７−トリアミンおよび２，４，６，７−四置換プテリジン化合物ならびにその合成方法および使用
PE20170694A1 (es)	2014-10-06	2017-05-26	Exicure Inc	Compuestos anti-tnf
US11083788B2 (en)	2014-10-10	2021-08-10	The Regents Of The University Of Michigan	Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
MA40920A (fr)	2014-11-07	2017-09-12	Takeda Vaccines Inc	Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
AU2015252119A1 (en)	2014-11-07	2016-05-26	Takeda Vaccines, Inc.	Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AU2015349680A1 (en)	2014-11-21	2017-06-08	Northwestern University	The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
MX387007B (es)	2014-12-10	2025-03-19	Glaxosmithkline Biologicals Sa	Una composición inmunogénica para usarse en el tratamiento o prevención de la infección por staphylococcus aureus.
CN107278206B (zh)	2014-12-19	2021-04-02	雷根尼桑斯公司	结合人c6的抗体及其用途
JP6885867B2 (ja)	2014-12-31	2021-06-16	チェックメイトファーマシューティカルズ，インコーポレイテッド	組合せ腫瘍免疫療法
EP3242940B1 (de)	2015-01-09	2023-03-29	Etubics Corporation	Verfahren und zusammensetzungen für kombinationsimmuntherapie
HRP20230416T1 (hr)	2015-01-15	2023-07-07	Pfizer Inc.	Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka
CA3012602A1 (en)	2015-01-30	2016-08-04	President And Fellows Of Harvard College	Peritumoral and intratumoral materials for cancer therapy
CA3014427A1 (en)	2015-02-13	2016-08-18	Icahn School Of Medicine At Mount Sinai	Rna containing compositions and methods of their use
US10813993B2 (en)	2015-03-03	2020-10-27	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Display platform from bacterial spore coat proteins
CN107530416A (zh)	2015-03-05	2018-01-02	西北大学	非神经侵染的病毒及其用途
WO2016145085A2 (en)	2015-03-09	2016-09-15	Celldex Therapeutics, Inc.	Cd27 agonists
US20180071380A1 (en)	2015-03-20	2018-03-15	The Regents Of The University Of Michigan	Immunogenic compositions for use in vaccination against bordetella
CN107427569B (zh)	2015-03-26	2022-12-30	Gpn疫苗有限公司	链球菌疫苗
CN107708756A (zh)	2015-04-10	2018-02-16	哈佛学院院长等	免疫细胞捕获装置及其制备和使用方法
EP3286213B1 (de)	2015-04-20	2021-08-04	Etubics Corporation	Verfahren und zusammensetzungen für eine kombinationsimmuntherapie
WO2016180852A1 (en)	2015-05-12	2016-11-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preparing antigen-specific t cells from an umbilical cord blood sample
KR20180006945A (ko)	2015-05-13	2018-01-19	아게누스 인코포레이티드	암 치료 및 예방용 백신
RU2017140856A (ru)	2015-05-26	2019-06-26	Огайо Стейт Инновейшн Фаундейшн	Стратегия вакцинации против вируса свиного гриппа вакциной на основе наночастиц
WO2016196846A2 (en)	2015-06-02	2016-12-08	Sanofi Pasteur Inc.	Engineered influenza antigenic polypeptides and immunogenic compositions thereof
DK3307878T3 (da)	2015-06-10	2021-10-11	Us Health	Fremgangsmåder til fremstilling og oprensning af nukleinsyreholdige sammensætninger
CN108472255A (zh) *	2015-06-26	2018-08-31	拜耳动物保健有限责任公司	调节胞质dna监测分子的方法
BR112018000087A2 (pt)	2015-07-21	2018-09-04	Pfizer Inc.	composições imunogênicas que compreendem antígenos de sacarídeos capsulares conjugados, kits que compreendem as mesmas e usos das mesmas
US20190030153A1 (en)	2015-07-22	2019-01-31	University Of Saskatchewan	Mycoplasma vaccines and uses thereof
US11034752B2 (en)	2015-08-12	2021-06-15	Massachusetts Institute Of Technology	Cell surface coupling of nanoparticles
EP4480544A3 (de)	2015-08-25	2025-03-26	Babita Agrawal	Immunmodulatorische zusammensetzungen und verfahren zur verwendung davon
EP3349717A4 (de)	2015-09-17	2019-04-17	JRX Biotechnology, Inc.	Ansätze zur verbesserung der hauthydrierung oder -befeuchtung
WO2017059280A1 (en)	2015-10-02	2017-04-06	The University Of North Carolina At Chapel Hill	Novel pan-tam inhibitors and mer/axl dual inhibitors
EP3359651A1 (de)	2015-10-05	2018-08-15	THE UNITED STATES OF AMERICA, represented by the S	Stamm des menschlichen rota-virus g9p[6] und verwendung als impfstoff
JP7098519B2 (ja)	2015-10-08	2022-07-11	ザガバナーズオブザユニバーシティオブアルバータ	Ｃ型肝炎ウイルスｅ１／ｅ２ヘテロダイマー及びそれを生成する方法
GB201518668D0 (en)	2015-10-21	2015-12-02	Glaxosmithkline Biolog Sa	Immunogenic Comosition
JP7171433B2 (ja)	2015-10-30	2022-11-15	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	Ｈｅｒ－２発現固形腫瘍の処置のための組成物および方法
WO2017085586A1 (en)	2015-11-20	2017-05-26	Pfizer Inc.	Immunogenic compositions for use in pneumococcal vaccines
WO2017120504A1 (en)	2016-01-08	2017-07-13	Durfee Paul N	Osteotropic nanoparticles for prevention or treatment of bone metastases
PL3407910T3 (pl)	2016-01-29	2022-08-16	Bavarian Nordic A/S	Rekombinowana zmodyfikowana szczepionka przeciwko wirusowi krowianki ankara (mva) przeciwko wirusowi zapalenia mózgu koni
EP3411475A4 (de)	2016-02-06	2019-09-11	President and Fellows of Harvard College	Rekapitulation der hämatopoietischen nische zur wiederherstellung der immunität
AU2017229991A1 (en)	2016-03-10	2018-10-04	Aperisys, Inc.	Antigen-binding fusion proteins with modified HSP70 domains
WO2017158421A1 (en)	2016-03-14	2017-09-21	University Of Oslo	Anti-viral engineered immunoglobulins
MY195541A (en)	2016-03-14	2023-01-31	Univ Oslo	Engineered Immunoglobulins With Altered Fcrn Binding
EP3436066A1 (de)	2016-04-01	2019-02-06	Checkmate Pharmaceuticals, Inc.	Fc-rezeptor-vermittelte wirkstofffreisetzung
SG11201808821WA (en)	2016-04-18	2018-11-29	Celldex Therapeutics Inc	Agonistic antibodies that bind human cd40 and uses thereof
WO2017189448A1 (en)	2016-04-25	2017-11-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bivalent immunogenic conjugate for malaria and typhoid
MX2018014086A (es)	2016-05-16	2019-09-18	Infectious Disease Res Inst	Formulacion que contiene agonista tlr y metodos de uso.
WO2017201390A1 (en)	2016-05-19	2017-11-23	The Regents Of The University Of Michigan	Novel adjuvant compositions
US20200148729A1 (en)	2016-05-21	2020-05-14	Infectious Disease Research Institute	Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
KR20190034504A (ko)	2016-05-27	2019-04-02	이투빅스 코포레이션	네오에피토프 백신 조성물 및 이의 사용 방법
AU2017273650B2 (en)	2016-06-01	2022-08-18	Access To Advanced Health Institute	Nanoalum particles containing a sizing agent
CA3026096A1 (en)	2016-06-02	2017-12-07	Sanofi Pasteur Inc.	Engineered influenza antigenic polypeptides and immunogenic compositions thereof
KR102529010B1 (ko)	2016-06-03	2023-05-04	사노피 파스퇴르 인코포레이티드	조작된 인플루엔자 헤마글루티닌 폴리펩티드의 변형
EP3468581A1 (de)	2016-06-13	2019-04-17	Torque Therapeutics, Inc.	Verfahren und zusammensetzungen zur förderung der immunzellenfunktionen
EP3468590B1 (de)	2016-06-13	2025-01-01	The United States of America, as represented by the Secretary, Department of Health and Human Services	Nukleinsäuren zur codierung von zika-virus-ähnlichen partikeln und deren verwendung in zika-virus-impfstoffen und diagnostischen tests
GB201610599D0 (en)	2016-06-17	2016-08-03	Glaxosmithkline Biologicals Sa	Immunogenic Composition
WO2017221072A2 (en)	2016-06-21	2017-12-28	University Of Oslo	Hla binding vaccine moieties and uses thereof
US10632185B2 (en)	2016-07-08	2020-04-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric west nile/zika viruses and methods of use
WO2018009604A1 (en)	2016-07-08	2018-01-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric dengue/zika viruses live-attenuated zika virus vaccines
MA45738A (fr)	2016-07-13	2019-05-22	Harvard College	Échafaudages mimétiques de cellules présentant l'antigène et procédés pour les préparer et les utiliser
CA3031797A1 (en)	2016-08-05	2018-02-08	Sanofi Pasteur, Inc.	Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3031799A1 (en)	2016-08-05	2018-02-08	Sanofi Pasteur, Inc.	Multivalent pneumococcal polysaccharide-protein conjugate composition
EP3504230A1 (de)	2016-08-23	2019-07-03	GlaxoSmithKline Biologicals SA	Fusionspeptide mit an kurze fragmente einer invarianten kette (cd74) gebundenen antigenen
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
WO2018053294A1 (en)	2016-09-16	2018-03-22	Infectious Disease Research Institute	Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
US11466292B2 (en)	2016-09-29	2022-10-11	Glaxosmithkline Biologicals Sa	Compositions and methods of treatment
EP3523435A1 (de) *	2016-10-07	2019-08-14	Secarna Pharmaceuticals GmbH & Co. KG	Immunsuppressionsumkehrende oligonukleotide mit hemmung der expression von cd39
US10172933B2 (en)	2016-10-31	2019-01-08	The United States Of America, As Represented By The Secretary Of Agriculture	Mosaic vaccines for serotype a foot-and-mouth disease virus
WO2018096396A1 (en)	2016-11-22	2018-05-31	University Of Oslo	Albumin variants and uses thereof
GB201620968D0 (en)	2016-12-09	2017-01-25	Glaxosmithkline Biologicals Sa	Adenovirus polynucleotides and polypeptides
EP3554538A2 (de)	2016-12-16	2019-10-23	Institute for Research in Biomedicine	Neuartige rekombinante rsv-f-präfusionsproteine und verwendungen davon
CA3050622A1 (en)	2017-01-20	2018-07-26	Pfizer Inc.	Immunogenic compositions for use in pneumococcal vaccines
WO2018160865A1 (en)	2017-03-01	2018-09-07	Charles Jeffrey Brinker	Active targeting of cells by monosized protocells
WO2018162450A1 (en)	2017-03-06	2018-09-13	Fundación Para La Investigación Médica Aplicada	New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
WO2018178265A1 (en)	2017-03-31	2018-10-04	Glaxosmithkline Intellectual Property Development Limited	Immunogenic composition, use and method of treatment
EP3600391A1 (de)	2017-03-31	2020-02-05	GlaxoSmithKline Intellectual Property Development Limited	Immunogene zusammensetzung, verwendung und verfahren zur behandlung
SG11201909265QA (en)	2017-04-19	2019-11-28	Inst Res Biomedicine	Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
US11696954B2 (en)	2017-04-28	2023-07-11	Exicure Operating Company	Synthesis of spherical nucleic acids using lipophilic moieties
MY204084A (en)	2017-06-11	2024-08-06	Molecular Express Inc	Methods and compositions for substance use disorder vaccine formulations and uses thereof
CA3067224A1 (en)	2017-06-15	2018-12-20	Infectious Disease Research Institute	Nanostructured lipid carriers and stable emulsions and uses thereof
EP3655031A1 (de)	2017-07-21	2020-05-27	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Immunogene zusammensetzungen gegen neisseria meningitidis
MX2020001820A (es)	2017-08-14	2020-03-20	Glaxosmithkline Biologicals Sa	Metodos para reforzar las respuestas inmunitarias.
WO2019035963A1 (en)	2017-08-16	2019-02-21	Ohio State Innovation Foundation	NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
JP7285828B2 (ja)	2017-09-05	2023-06-02	トルクセラピューティクス，インコーポレイテッド	治療用タンパク質組成物ならびにその作製および使用方法
WO2019048936A1 (en)	2017-09-07	2019-03-14	University Of Oslo	VACCINE MOLECULES
EP3678698A1 (de)	2017-09-07	2020-07-15	University Of Oslo	Impfstoffmoleküle
EP3679138B1 (de)	2017-09-08	2023-03-22	MiNA Therapeutics Limited	Hnf4a-sarna-zusammensetzungen und verfahren zur verwendung
CA3078223A1 (en)	2017-09-08	2019-03-14	Infectious Disease Research Institute	Liposomal formulations comprising saponin and methods of use
WO2019089755A1 (en)	2017-10-31	2019-05-09	Western Oncolytics Ltd.	Platform oncolytic vector for systemic delivery
CA3081586A1 (en)	2017-11-03	2019-05-09	Takeda Vaccines, Inc.	Zika vaccines and immunogenic compositions, and methods of using the same
WO2019090138A2 (en)	2017-11-04	2019-05-09	Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno	Immunogenic conjugates and methods of use thereof
CN111801116B (zh) *	2017-12-15	2024-11-26	礼蓝动物保健有限公司	免疫刺激性组合物
WO2019126197A1 (en)	2017-12-18	2019-06-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bacterial polysaccharide-conjugated carrier proteins and use thereof
CA3086205A1 (en)	2017-12-19	2019-06-27	Massachusetts Institute Of Technology	Antigen-adjuvant coupling reagents and methods of use
GB201721576D0 (en)	2017-12-21	2018-02-07	Glaxosmithkline Biologicals Sa	Hla antigens and glycoconjugates thereof
GB201721582D0 (en)	2017-12-21	2018-02-07	Glaxosmithkline Biologicals Sa	S aureus antigens and immunogenic compositions
CN111629751B (zh)	2018-01-22	2025-02-21	美国政府(由卫生和人类服务部的部长所代表)	广泛保护性灭活流感病毒疫苗
EP3743102A1 (de)	2018-01-26	2020-12-02	Nantcell, Inc.	Zusammensetzungen und verfahren zur kombination eines krebsimpfstoffs und einer immunologischen adjuvanten therapie
WO2019160866A2 (en)	2018-02-13	2019-08-22	Checkmate Pharmaceuticals, Inc.	Compositions and methods for tumor immunotherapy
JP2021513840A (ja)	2018-02-16	2021-06-03	２エーファーマアーベー	自己免疫疾患の処置のためのパルボウイルス構造タンパク質
EP3527223A1 (de)	2018-02-16	2019-08-21	2A Pharma AB	Mutiertes parvovirus-strukturprotein
TWI776024B (zh)	2018-02-28	2022-09-01	美商輝瑞大藥廠	Il-15變體及其用途
US11633471B2 (en)	2018-03-06	2023-04-25	Unm Rainforest Innovations	Compositions and methods for reducing serum triglycerides
EP3774884B1 (de)	2018-03-28	2023-12-06	Sanofi Pasteur Inc.	Verfahren zur erzeugung von breit schützenden impfstoffzusammensetzungen mit hämagglutinin
WO2019195291A1 (en)	2018-04-03	2019-10-10	Sanofi	Antigenic respiratory syncytial virus polypeptides
WO2019195314A2 (en)	2018-04-03	2019-10-10	Sanofi	Antigenic epstein barr virus polypeptides
CN112512565A (zh)	2018-04-03	2021-03-16	赛诺菲	抗原性流感-铁蛋白多肽
EP3773698A1 (de)	2018-04-03	2021-02-17	Sanofi	Ferritinproteine
CA3095174A1 (en)	2018-04-03	2019-10-10	Sanofi	Antigenic ospa polypeptides
SG11202009647VA (en)	2018-04-09	2020-10-29	Checkmate Pharmaceuticals	Packaging oligonucleotides into virus-like particles
US20210198374A1 (en)	2018-04-17	2021-07-01	Celldex Therapeutics, Inc.	Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
KR20230146098A (ko)	2018-05-23	2023-10-18	화이자 인코포레이티드	GUCY2c에 특이적인 항체 및 이의 용도
JP7384835B2 (ja)	2018-05-23	2023-11-21	ファイザー・インク	Ｃｄ３に特異的な抗体及びその使用
JP2021526831A (ja)	2018-06-12	2021-10-11	グラクソスミスクラインバイオロジカルズソシエテアノニム	アデノウイルスポリヌクレオチド及びポリペプチド
WO2020014656A1 (en)	2018-07-13	2020-01-16	University Of Georgia Research Foundation	Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof
CA3106291A1 (en)	2018-07-19	2020-01-23	Glaxosmithkline Biologicals Sa	Processes for preparing dried polysaccharides
CN112601545A (zh)	2018-08-07	2021-04-02	葛兰素史密丝克莱恩生物有限公司	工艺和疫苗
US11260119B2 (en)	2018-08-24	2022-03-01	Pfizer Inc.	Escherichia coli compositions and methods thereof
US12239699B2 (en)	2018-09-11	2025-03-04	Shanghai Public Health Clinical Center	Immunogen for broad-spectrum influenza vaccine and application thereof
WO2020061129A1 (en)	2018-09-19	2020-03-26	President And Fellows Of Harvard College	Compositions and methods for labeling and modulation of cells in vitro and in vivo
WO2020068798A1 (en)	2018-09-24	2020-04-02	Guo Jimin	Living mammalian cells modified with functional modular nanoparticles
WO2020117590A1 (en)	2018-12-04	2020-06-11	The Rockefeller University	Hiv vaccine immunogens
WO2020115171A1 (en)	2018-12-06	2020-06-11	Glaxosmithkline Biologicals Sa	Immunogenic compositions
EP3894547A1 (de)	2018-12-12	2021-10-20	The United States of America, as represented by The Secretary, Department of Health and Human Services	Rekombinanter mumps-virus-impfstoff, der genotyp-g-fusion und hämagglutinin-neuraminidaseproteine exprimiert
JP7551618B2 (ja)	2018-12-12	2024-09-17	グラクソスミスクラインバイオロジカルズソシエテアノニム	Ｏ－結合型グリコシル化のための修飾キャリアタンパク質
CA3120922A1 (en)	2018-12-12	2020-06-18	Pfizer Inc.	Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
WO2020123989A1 (en)	2018-12-14	2020-06-18	University Of Georgia Research Foundation, Inc.	Crimean-congo hemorrhagic fever virus replicon particles and use thereof
WO2020128893A1 (en)	2018-12-21	2020-06-25	Pfizer Inc.	Combination treatments of cancer comprising a tlr agonist
US20220184158A1 (en)	2018-12-21	2022-06-16	Glaxosmithkline Biologicals Sa	Methods of inducing an immune response
GB201901608D0 (en)	2019-02-06	2019-03-27	Vib Vzw	Vaccine adjuvant conjugates
WO2020176716A1 (en)	2019-02-28	2020-09-03	Brinker C Jeffrey	Modular metal–organic polyhedra superassembly compositions
CN114269373A (zh)	2019-04-02	2022-04-01	赛诺菲	抗原性多聚呼吸道合胞病毒多肽
EP3952906A1 (de)	2019-04-10	2022-02-16	Pfizer Inc.	Immunogene zusammensetzungen mit konjugierten kapselförmigen saccharidantigenen, kits damit und verwendungen davon
WO2020212461A1 (en)	2019-04-18	2020-10-22	Glaxosmithkline Biologicals Sa	Antigen binding proteins and assays
WO2020234300A1 (en)	2019-05-20	2020-11-26	Valneva Se	A subunit vaccine for treatment or prevention of a respiratory tract infection
MX2021014363A (es)	2019-05-25	2022-02-21	Infectious Disease Res Inst	Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
EP3980056A4 (de)	2019-05-31	2023-03-29	Universidad De Chile	Immunogene formulierung, die einen schutz gegen shiga-toxin-produzierende escherichia coli (stec) induziert
EP3770269A1 (de)	2019-07-23	2021-01-27	GlaxoSmithKline Biologicals S.A.	Quantifizierung von biokonjugatglykosylierung
AU2020325645A1 (en)	2019-08-05	2022-02-17	Glaxosmithkline Biologicals Sa	Immunogenic composition
US20220280491A1 (en)	2019-08-30	2022-09-08	University Of Rochester	Septin inhibitors for treatment of cancers
AU2020351168A1 (en)	2019-09-18	2022-04-14	Children's Medical Center Corporation	An anaplastic lymphoma kinase (ALK) cancer vaccine and methods of use
EP3799884A1 (de)	2019-10-01	2021-04-07	GlaxoSmithKline Biologicals S.A.	Immunogene zusammensetzungen
IL292494A (en)	2019-11-01	2022-06-01	Pfizer	Escherichia coli compositions and methods thereof
WO2021097347A1 (en)	2019-11-15	2021-05-20	Infectious Disease Research Institute	Rig-i agonist and adjuvant formulation for tumor treatment
WO2021099982A1 (en)	2019-11-22	2021-05-27	Glaxosmithkline Biologicals Sa	Dosage and administration of a bacterial saccharide glycoconjugate vaccine
BR112022010228A2 (pt)	2019-12-17	2022-09-06	Us Health	Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas
PE20230160A1 (es)	2019-12-17	2023-02-01	Pfizer	Anticuerpos especificos para cd47, pd-l1 y sus usos
IL295632A (en)	2020-02-23	2022-10-01	Pfizer	Escherichia coli preparations and their methods
JP2023515829A (ja)	2020-02-28	2023-04-14	サノフィパスツールインコーポレイテッド	小児対象のための高用量インフルエンザワクチン
US11213482B1 (en)	2020-03-05	2022-01-04	University of Pittsburgh—Of the Commonwealth System of Higher Educat	SARS-CoV-2 subunit vaccine and microneedle array delivery system
EP4138894A4 (de)	2020-04-20	2024-06-26	The University of Saskatchewan	Zusammensetzungen und verfahren zur vorbeugung, kontrolle und diagnose mykobakterieller infektionen
AU2021308586A1 (en)	2020-07-17	2023-03-02	Pfizer Inc.	Therapeutic antibodies and their uses
JP7407081B2 (ja)	2020-07-20	2023-12-28	三菱重工機械システム株式会社	印刷機および印刷機の後片付け方法
US20230310323A1 (en)	2020-09-04	2023-10-05	Access To Advanced Health Institute	Co-lyophilized rna and nanostructured lipid carrier
WO2022066973A1 (en)	2020-09-24	2022-03-31	Fred Hutchinson Cancer Research Center	Immunotherapy targeting pbk or oip5 antigens
US20250018036A1 (en)	2020-09-24	2025-01-16	Fred Hutchinson Cancer Center	Immunotherapy targeting sox2 antigens
US20230372464A1 (en)	2020-10-07	2023-11-23	Valneva Sweden Ab	Cholera vaccine formulation
EP4234585A4 (de)	2020-10-23	2024-10-02	Jiangsu Provincial Center for Disease Control and Prevention (Public Health Research Institute of Jiangsu Province)	Fusionsprotein und anwendung davon
US12138302B2 (en)	2020-10-27	2024-11-12	Pfizer Inc.	Escherichia coli compositions and methods thereof
IL302362A (en)	2020-10-27	2023-06-01	Pfizer	Escherichia coli compositions and methods thereof
MX2023005221A (es)	2020-11-04	2023-05-16	Pfizer	Composiciones inmunogenicas para uso en vacunas neumococicas.
JP2023549736A (ja)	2020-11-10	2023-11-29	ファイザー・インク	コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
US20220202923A1 (en)	2020-12-23	2022-06-30	Pfizer Inc.	E. coli fimh mutants and uses thereof
US20240050561A1 (en)	2020-12-23	2024-02-15	Access To Advanced Health Institute	Solanesol vaccine adjuvants and methods of preparing same
US20240299510A1 (en)	2020-12-31	2024-09-12	The United States Of America,As Represented By The Secretary,Department Of Health And Human Services	Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
JP2024510717A (ja)	2021-02-22	2024-03-11	グラクソスミスクラインバイオロジカルズソシエテアノニム	免疫原性組成物、使用及び方法
WO2022207793A1 (en)	2021-03-31	2022-10-06	Vib Vzw	Vaccine compositions for trypanosomatids
EP4319802A2 (de)	2021-04-09	2024-02-14	Valneva SE	Kombinationsimpfstoff gegen menschliches metapneumovirus
CN117545773A (zh)	2021-04-09	2024-02-09	塞德斯医疗公司	抗ilt4的抗体、双特异性抗ilt4/pd-l1抗体及其用途
CA3215344A1 (en)	2021-04-30	2022-11-03	Kalivir Immunotherapeutics, Inc.	Oncolytic viruses for modified mhc expression
US20220387576A1 (en)	2021-05-28	2022-12-08	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20230175284A (ko)	2021-05-28	2023-12-29	화이자 인코포레이티드	접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
MX2024000330A (es)	2021-07-16	2024-01-25	Univ Illinois	Vacuna universal para virus de influenza en base a la proteina m2 tetramerica incorporada en nanodiscos.
JP2024532763A (ja)	2021-08-11	2024-09-10	サノフィパスツールインコーポレイテッド	切断型インフルエンザノイラミニダーゼおよびこれを使用する方法
JP2024537180A (ja)	2021-10-08	2024-10-10	サノフィパスツールインコーポレイテッド	多価インフルエンザワクチン
CA3236924A1 (en)	2021-11-05	2023-05-11	Sanofi	Respiratory syncytial virus rna vaccine
IL312545A (en)	2021-11-05	2024-07-01	Sanofi Pasteur Inc	Multivalent Influenza Vaccines Including Hemagglutinin and Recombinant Neuraminidase and Methods of Using Them
IL312502A (en)	2021-11-05	2024-07-01	Sanofi Sa	Hybrid multivalent influenza vaccines containing hemagglutinin and neuraminidase and methods of using them
WO2023077521A1 (en)	2021-11-08	2023-05-11	Celldex Therapeutics, Inc	Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023083964A1 (en)	2021-11-11	2023-05-19	2A Pharma Ab	Parvovirus structural protein against beta- and gamma-hpv
JP2024542635A (ja)	2021-11-30	2024-11-15	サノフィパスツールインコーポレイテッド	ヒトメタニューモウイルスワクチン
AU2022399574A1 (en)	2021-11-30	2024-07-11	Sanofi Pasteur Inc.	Human metapneumovirus viral vector-based vaccines
WO2023114727A1 (en)	2021-12-13	2023-06-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bacteriophage lambda-vaccine system
JP2025500880A (ja)	2021-12-17	2025-01-15	サノフイ	ライム病ｒｎａワクチン
AU2023207315A1 (en)	2022-01-13	2024-06-27	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4469565A1 (de)	2022-01-27	2024-12-04	Sanofi Pasteur	Modifizierte vero-zellen und verfahren zur verwendung davon zur virusherstellung
WO2023161817A1 (en)	2022-02-25	2023-08-31	Pfizer Inc.	Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023177579A1 (en)	2022-03-14	2023-09-21	Sanofi Pasteur Inc.	Machine-learning techniques in protein design for vaccine generation
IL316761A (en)	2022-05-06	2025-01-01	Sanofi Sa	Marker sequences for nucleic acid vaccines
EP4522208A1 (de)	2022-05-11	2025-03-19	Pfizer Inc.	Verfahren zur herstellung von impfstoffformulierungen mit konservierungsmitteln
EP4531899A1 (de)	2022-06-01	2025-04-09	Valneva Austria GmbH	Clostridium-difficile-impfstoff
KR20250029868A (ko)	2022-06-29	2025-03-05	버베리안 노딕 에이/에스	재조합 변형 saRNA (VRP) 및 백시니아 바이러스 안카라 (MVA) 프라임-부스트 요법
WO2024052882A1 (en)	2022-09-09	2024-03-14	Access To Advanced Health Institute	Immunogenic vaccine composition incorporating a saponin
WO2024094881A1 (en)	2022-11-04	2024-05-10	Sanofi	Respiratory syncytial virus rna vaccination
WO2024110827A1 (en)	2022-11-21	2024-05-30	Pfizer Inc.	Methods for preparing conjugated capsular saccharide antigens and uses thereof
WO2024110839A2 (en)	2022-11-22	2024-05-30	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en)	2022-12-01	2024-06-06	Pfizer Inc.	Pneumococcal conjugate vaccine formulations
WO2024121380A1 (en)	2022-12-08	2024-06-13	Pierre Fabre Medicament	Vaccinal composition and adjuvant
WO2024127215A2 (en)	2022-12-13	2024-06-20	Pfizer Inc.	Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
AR131438A1 (es)	2022-12-20	2025-03-19	Sanofi Sa	VACUNA DE ARNm DE RINOVIRUS
WO2024149832A1 (en)	2023-01-12	2024-07-18	Bavarian Nordic A/S	RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
WO2024163327A1 (en)	2023-01-30	2024-08-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery
WO2024166008A1 (en)	2023-02-10	2024-08-15	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12263213B2 (en)	2023-03-02	2025-04-01	Sanofi Pasteur	Compositions for use in treatment of Chlamydia
WO2024186635A2 (en)	2023-03-03	2024-09-12	Celldex Therapeutics, Inc.	Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024201324A2 (en)	2023-03-30	2024-10-03	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en)	2023-04-14	2024-10-17	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202500750A (zh)	2023-05-05	2025-01-01	法商賽諾菲公司	用於治療痤瘡的組成物
US20250009865A1 (en)	2023-05-10	2025-01-09	Sanofi	Combination respiratory mrna vaccines
WO2024233873A1 (en)	2023-05-11	2024-11-14	Sanofi Pasteur Inc.	Respiratory syncytial virus vaccine and methods of use
WO2024241172A2 (en)	2023-05-19	2024-11-28	Glaxosmithkline Biologicals Sa	Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2024246358A1 (en)	2023-06-01	2024-12-05	Sanofi	Thermostable compositions comprising mrna lipid nanoparticles
WO2025006737A1 (en)	2023-06-30	2025-01-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
WO2025017202A2 (en)	2023-07-19	2025-01-23	Sanofi	Porphyromonas gingivalis antigenic constructs
US20250090650A1 (en)	2023-09-06	2025-03-20	Sanofi	Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
WO2025057078A1 (en)	2023-09-14	2025-03-20	Pfizer Inc.	Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2034118A1 (en) †	1970-07-09	1972-01-13	Seinfeld, Hugo, Brendel, Walter, Prof Dr . 8000 München	Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins
US4956296A (en) *	1987-06-19	1990-09-11	Genex Corporation	Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
US5059519A (en)	1986-07-01	1991-10-22	University Of Massachusetts Medical School	Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases
CA1339596C (en)	1987-08-07	1997-12-23	New England Medical Center Hospitals, Inc.	Viral expression inhibitors
US5786189A (en) *	1989-11-29	1998-07-28	Smithkline Beecham Biologicals (S.A.)	Vaccine
US5248670A (en)	1990-02-26	1993-09-28	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides for inhibiting herpesviruses
JPH04352724A (ja) *	1990-07-27	1992-12-07	Mitsui Toatsu Chem Inc	免疫調節型治療剤
EP0468520A3 (en) *	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
DE69126710T2 (de)	1990-08-16	1998-01-15	Isis Pharmaceutical, Inc., Carlsbad, Calif.	Oligonukleotide zur modulation der effekte von cytomegalovirusinfektionen
US5234811A (en) *	1991-09-27	1993-08-10	The Scripps Research Institute	Assay for a new gaucher disease mutation
CA2122132A1 (en)	1991-11-18	1993-05-27	Tse Wen Chang	Anti-sense oligonucleotides for isotype-specific suppression of immunoglobulin production
ES2095657T3 (es)	1992-07-24	1997-02-16	Kumiai Chemical Industry Co	Derivado de triazol, procedimiento de obtencion del mismo, un agente de control de plagas y metodo de control de plagas.
US5585479A (en) *	1992-07-24	1996-12-17	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human ELAM-I RNA
ATE162198T1 (de) †	1992-07-27	1998-01-15	Hybridon Inc	Oligonukleotid alkylphosphonothiate
US5840497A (en)	1993-06-11	1998-11-24	The Commonwealth Of Australia Commonwealth Scientific And Industrial Research Organization	Method for specific silencing of genes by DNA methylation
WO1995026204A1 (en) *	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
EP1167378B1 (de) *	1994-07-15	2011-05-11	University of Iowa Research Foundation	Immunomodulatorische Oligonukleotide
US5629052A (en)	1995-02-15	1997-05-13	The Procter & Gamble Company	Method of applying a curable resin to a substrate for use in papermaking

1995
- 1995-02-07 EP EP01202813A patent/EP1167378B1/de not_active Expired - Lifetime
- 1995-02-07 DK DK95911630.2T patent/DK0772619T4/da active
- 1995-02-07 EP EP95911630A patent/EP0772619B2/de not_active Expired - Lifetime
- 1995-02-07 WO PCT/US1995/001570 patent/WO1996002555A1/en active IP Right Grant
- 1995-02-07 AT AT95911630T patent/ATE328890T1/de active
- 1995-02-07 AT AT01202813T patent/ATE509102T1/de not_active IP Right Cessation
- 1995-02-07 AU AU19127/95A patent/AU713040B2/en not_active Expired
- 1995-02-07 CA CA002560114A patent/CA2560114A1/en not_active Abandoned
- 1995-02-07 AT AT01202811T patent/ATE420171T1/de not_active IP Right Cessation
- 1995-02-07 ES ES95911630T patent/ES2267100T5/es not_active Expired - Lifetime
- 1995-02-07 PT PT95911630T patent/PT772619E/pt unknown
- 1995-02-07 ES ES01202813T patent/ES2366201T3/es not_active Expired - Lifetime
- 1995-02-07 US US08/386,063 patent/US6194388B1/en not_active Expired - Lifetime
- 1995-02-07 JP JP50499196A patent/JP3468773B2/ja not_active Expired - Lifetime
- 1995-02-07 EP EP01202811A patent/EP1167377B2/de not_active Expired - Lifetime
- 1995-02-07 CA CA002194761A patent/CA2194761C/en not_active Expired - Lifetime
- 1995-02-07 ES ES01202811T patent/ES2320315T5/es not_active Expired - Lifetime
- 1995-02-07 EP EP01202814A patent/EP1167379A3/de not_active Ceased
- 1995-02-07 DE DE69535905T patent/DE69535905D1/de not_active Expired - Lifetime
- 1995-02-07 DE DE69535036T patent/DE69535036T3/de not_active Expired - Lifetime
2002
- 2002-05-13 HK HK02103584.4A patent/HK1043598A1/zh unknown
- 2002-06-26 HK HK02104746.7A patent/HK1044949B/zh not_active IP Right Cessation
- 2002-06-26 HK HK02104747.6A patent/HK1044950A1/zh not_active IP Right Cessation
- 2002-10-16 JP JP2002302338A patent/JP2003144184A/ja not_active Withdrawn
2003
- 2003-06-23 JP JP2003178740A patent/JP2004024261A/ja not_active Withdrawn
- 2003-06-23 JP JP2003178741A patent/JP4126252B2/ja not_active Expired - Lifetime
2004
- 2004-03-11 JP JP2004069838A patent/JP2004215670A/ja not_active Withdrawn
2008
- 2008-01-25 JP JP2008015654A patent/JP2008169216A/ja not_active Withdrawn
2009
- 2009-03-10 JP JP2009057160A patent/JP2009148296A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CA2194761A1 (en)	1996-02-01
JP2008169216A (ja)	2008-07-24
JP2004215670A (ja)	2004-08-05
PT772619E (pt)	2006-10-31
JPH10506265A (ja)	1998-06-23
EP1167378A2 (de)	2002-01-02
JP2004043466A (ja)	2004-02-12
ES2267100T5 (es)	2011-04-08
EP1167377B2 (de)	2012-08-08
ATE509102T1 (de)	2011-05-15
ATE420171T1 (de)	2009-01-15
DE69535036T2 (de)	2007-01-18
EP1167378B1 (de)	2011-05-11
JP2009148296A (ja)	2009-07-09
AU713040B2 (en)	1999-11-18
HK1044949B (zh)	2012-01-27
JP2003144184A (ja)	2003-05-20
JP4126252B2 (ja)	2008-07-30
DK0772619T4 (da)	2011-02-21
EP1167379A3 (de)	2004-09-08
AU1912795A (en)	1996-02-16
ES2320315T5 (es)	2012-12-05
EP1167377A2 (de)	2002-01-02
EP0772619B1 (de)	2006-06-07
HK1044950A1 (zh)	2002-11-08
EP1167378A3 (de)	2005-08-17
WO1996002555A1 (en)	1996-02-01
ES2267100T3 (es)	2007-03-01
EP1167377B1 (de)	2009-01-07
HK1044949A1 (en)	2002-11-08
CA2194761C (en)	2006-12-19
ES2366201T3 (es)	2011-10-18
US6194388B1 (en)	2001-02-27
EP0772619B2 (de)	2010-12-08
ATE328890T1 (de)	2006-06-15
EP0772619A1 (de)	1997-05-14
CA2560114A1 (en)	1996-02-01
EP1167377A3 (de)	2004-09-08
EP1167379A2 (de)	2002-01-02
JP2004024261A (ja)	2004-01-29
DE69535905D1 (de)	2009-02-26
DE69535036T3 (de)	2011-07-07
HK1043598A1 (zh)	2002-09-20
ES2320315T3 (es)	2009-05-21
DK0772619T3 (da)	2006-10-09
JP3468773B2 (ja)	2003-11-17

Publication	Publication Date	Title
DE69535036D1 (de)	2006-07-20	Immunomodulatorische oligonukleotide
ZA9811848B (en)	2000-06-26	Vaccine.
DE69727183D1 (de)	2004-02-19	Angetriebenes Handstück
EP0674876A3 (de)	1995-12-27	Chirurgisches Klammerinstrument.
ZA9811585B (en)	2000-06-19	Medical device.
EP0677273A3 (de)	1995-12-13	Chirurgisches Klammergerät.
DE69816696D1 (de)	2003-09-04	Pneumatisches chirurgisches Handstück
IS4812A (is)	1998-07-28	Samsett meðferð fyrir beingisnun
IT1292837B1 (it)	1999-02-11	Apparecchio chirurgico per biopsia.
DZ2283A1 (fr)	2002-12-25	Composition de vaccin.
IT1302338B1 (it)	2000-09-05	Dispositivo per l'azionamento del freno di un veicolo.
ZA971250B (en)	1997-08-27	Dental syringe.
FI965196L (fi)	1996-12-23	HIV-infektion yhdistelmähoito
ZA9810445B (en)	1999-07-01	Novel bone surgical device.
ZA984696B (en)	1999-01-04	Vaccine compositions V.
ES1027473Y (es)	1995-02-16	Boton quirurgico de traccion ortodoncia.
ITBO930113V0 (it)	1993-05-19	supporto per strumenti odontoiatrici accessori.
ES1028663Y (es)	1995-07-01	Depresor lingual.
IT1274909B (it)	1997-07-25	Manipolo endoorale per riprese di video-immagini.
ES1030157Y (es)	1996-01-16	Depresor lingual.
BR9401338A (pt)	1995-10-24	Bocal para lâmpadas de encaixe por pressão das mesmas
ITBO970569A0 (it)	1997-09-22	Fascetta multiuso per chirurgia ortopedica.
ES1025872Y (es)	1994-09-01	Maquina de traccion cervical.
IT1290694B1 (it)	1998-12-10	Manipolo dentale per la rimozione del tartaro.
ZA987303B (en)	2000-02-14	Vaccine.

Legal Events

Date	Code	Title	Description
2007-06-14	8363	Opposition against the patent
2011-02-10	8366	Restricted maintained after opposition proceedings